Contact, publication, and social network information about Harvard faculty and fellows. Harvard Catalyst Profiles
Keywords
Last Name
Institution

Richard David Gelber, Ph.D.

TitleProfessor of Pediatrics (Biostatistics)
InstitutionDana-Farber Cancer Institute
DepartmentPediatrics
AddressDana-Farber Cancer Institute
Dept of Biostatistics and Computational Biology
450 Brookline Ave
Boston MA 02215
Phone617/632-3603
Fax617/632-2444
Other Positions
TitleProfessor in the Department of Biostatistics
InstitutionHarvard School of Public Health
DepartmentBiostatistics


 Bibliographic 
 selected publications
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
List All   |   Timeline
  1. Partridge AH, Gelber S, Gelber R. Reply to d. Serraino et Al. J Clin Oncol. 2014 Jan 10; 32(2):161.
    View in: PubMed
  2. Huober J, Cole BF, Rabaglio M, Giobbie-Hurder A, Wu J, Ejlertsen B, Bonnefoi H, Forbes JF, Neven P, Láng I, Smith I, Wardley A, Price KN, Goldhirsch A, Coates AS, Colleoni M, Gelber RD, Thürlimann B. Symptoms of endocrine treatment and outcome in the BIG 1-98 study. Breast Cancer Res Treat. 2014 Jan; 143(1):159-69.
    View in: PubMed
  3. Regan MM, Pagani O, Fleming GF, Walley BA, Price KN, Rabaglio M, Maibach R, Ruepp B, Coates AS, Goldhirsch A, Colleoni M, Gelber RD, Francis PA. Adjuvant treatment of premenopausal women with endocrine-responsive early breast cancer: Design of the TEXT and SOFT trials. Breast. 2013 Dec; 22(6):1094-100.
    View in: PubMed
  4. Goldhirsch A, Winer EP, Coates AS, Gelber RD, Piccart-Gebhart M, Thürlimann B, Senn HJ. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol. 2013 Sep; 24(9):2206-23.
    View in: PubMed
  5. Metzger-Filho O, Sun Z, Viale G, Price KN, Crivellari D, Snyder RD, Gelber RD, Castiglione-Gertsch M, Coates AS, Goldhirsch A, Cardoso F. Patterns of Recurrence and outcome according to breast cancer subtypes in lymph node-negative disease: results from international breast cancer study group trials VIII and IX. J Clin Oncol. 2013 Sep 1; 31(25):3083-90.
    View in: PubMed
  6. Goldhirsch A, Gelber RD, Piccart-Gebhart MJ, de Azambuja E, Procter M, Suter TM, Jackisch C, Cameron D, Weber HA, Heinzmann D, Dal Lago L, McFadden E, Dowsett M, Untch M, Gianni L, Bell R, Köhne CH, Vindevoghel A, Andersson M, Brunt AM, Otero-Reyes D, Song S, Smith I, Leyland-Jones B, Baselga J. 2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial. Lancet. 2013 Sep 21; 382(9897):1021-8.
    View in: PubMed
  7. Giobbie-Hurder A, Gelber RD, Regan MM. Challenges of guarantee-time bias. J Clin Oncol. 2013 Aug 10; 31(23):2963-9.
    View in: PubMed
  8. Partridge AH, Gelber S, Piccart-Gebhart MJ, Focant F, Scullion M, Holmes E, Winer EP, Gelber RD. Effect of age on breast cancer outcomes in women with human epidermal growth factor receptor 2-positive breast cancer: results from a herceptin adjuvant trial. J Clin Oncol. 2013 Jul 20; 31(21):2692-8.
    View in: PubMed
  9. Metzger-Filho O, Procter M, de Azambuja E, Leyland-Jones B, Gelber RD, Dowsett M, Loi S, Saini KS, Cameron D, Untch M, Smith I, Gianni L, Baselga J, Jackisch C, Bell R, Sotiriou C, Viale G, Piccart-Gebhart M. Magnitude of Trastuzumab Benefit in Patients With HER2-Positive, Invasive Lobular Breast Carcinoma: Results From the HERA Trial. J Clin Oncol. 2013 Jun 1; 31(16):1954-60.
    View in: PubMed
  10. Galimberti V, Cole BF, Zurrida S, Viale G, Luini A, Veronesi P, Baratella P, Chifu C, Sargenti M, Intra M, Gentilini O, Mastropasqua MG, Mazzarol G, Massarut S, Garbay JR, Zgajnar J, Galatius H, Recalcati A, Littlejohn D, Bamert M, Colleoni M, Price KN, Regan MM, Goldhirsch A, Coates AS, Gelber RD, Veronesi U. Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23-01): a phase 3 randomised controlled trial. Lancet Oncol. 2013 Apr; 14(4):297-305.
    View in: PubMed
  11. Crivellari D, Gray KP, Dellapasqua S, Puglisi F, Ribi K, Price KN, Láng I, Gianni L, Spazzapan S, Pinotti G, Lüthi JM, Gelber RD, Regan MM, Colleoni M, Castiglione-Gertsch M, Maibach R, Rabaglio M, Coates AS, Goldhirsch A. Adjuvant pegylated liposomal doxorubicin for older women with endocrine nonresponsive breast cancer who are NOT suitable for a "standard chemotherapy regimen": The CASA randomized trial. Breast. 2013 Apr; 22(2):130-7.
    View in: PubMed
  12. Pestalozzi BC, Holmes E, de Azambuja E, Metzger-Filho O, Hogge L, Scullion M, Láng I, Wardley A, Lichinitser M, Sanchez RI, Müller V, Dodwell D, Gelber RD, Piccart-Gebhart MJ, Cameron D. CNS relapses in patients with HER2-positive early breast cancer who have and have not received adjuvant trastuzumab: a retrospective substudy of the HERA trial (BIG 1-01). Lancet Oncol. 2013 Mar; 14(3):244-8.
    View in: PubMed
  13. Oakman C, Francis PA, Crown J, Quinaux E, Buyse M, De Azambuja E, Margeli Vila M, Andersson M, Nordenskjöld B, Jakesz R, Thürlimann B, Gutiérrez J, Harvey V, Punzalan L, Dell'orto P, Larsimont D, Steinberg I, Gelber RD, Piccart-Gebhart M, Viale G, Di Leo A. Overall survival benefit for sequential doxorubicin-docetaxel compared with concurrent doxorubicin and docetaxel in node-positive breast cancer--8-year results of the Breast International Group 02-98 phase III trial. Ann Oncol. 2013 May; 24(5):1203-11.
    View in: PubMed
  14. Ewertz M, Gray KP, Regan MM, Ejlertsen B, Price KN, Thürlimann B, Bonnefoi H, Forbes JF, Paridaens RJ, Rabaglio M, Gelber RD, Colleoni M, Láng I, Smith IE, Coates AS, Goldhirsch A, Mouridsen HT. Obesity and risk of recurrence or death after adjuvant endocrine therapy with letrozole or tamoxifen in the breast international group 1-98 trial. J Clin Oncol. 2012 Nov 10; 30(32):3967-75.
    View in: PubMed
  15. Goldhirsch A, Gelber RD. Breast cancer: Anastrozole and fulvestrant--combination to unlock efficacy. Nat Rev Clin Oncol. 2012 Oct; 9(10):556-7.
    View in: PubMed
  16. Karlsson P, Cole BF, Chua BH, Price KN, Lindtner J, Collins JP, Kovács A, Thürlimann B, Crivellari D, Castiglione-Gertsch M, Forbes JF, Gelber RD, Goldhirsch A, Gruber G. Patterns and risk factors for locoregional failures after mastectomy for breast cancer: an International Breast Cancer Study Group report. Ann Oncol. 2012 Nov; 23(11):2852-8.
    View in: PubMed
  17. Dellapasqua S, Bagnardi V, Regan MM, Rotmensz N, Mastropasqua MG, Viale G, Maiorano E, Price KN, Gelber RD, Castiglione-Gertsch M, Goldhirsch A, Colleoni M. A risk score based on histopathological features predicts higher risk of distant recurrence in premenopausal patients with lymph node-negative endocrine-responsive breast cancer. Breast. 2012 Oct; 21(5):621-8.
    View in: PubMed
  18. Huober J, Gelber S, Goldhirsch A, Coates AS, Viale G, Ohlschlegel C, Price KN, Gelber RD, Regan MM, Thürlimann B. Prognosis of medullary breast cancer: analysis of 13 International Breast Cancer Study Group (IBCSG) trials. Ann Oncol. 2012 Nov; 23(11):2843-51.
    View in: PubMed
  19. Ribi K, Aldridge J, Phillips KA, Thompson A, Harvey V, Thürlimann B, Cardoso F, Pagani O, Coates AS, Goldhirsch A, Price KN, Gelber RD, Bernhard J. Subjective cognitive complaints one year after ceasing adjuvant endocrine treatment for early-stage breast cancer. Br J Cancer. 2012 May 8; 106(10):1618-25.
    View in: PubMed
  20. Regan MM, Leyland-Jones B, Bouzyk M, Pagani O, Tang W, Kammler R, Dell'orto P, Biasi MO, Thürlimann B, Lyng MB, Ditzel HJ, Neven P, Debled M, Maibach R, Price KN, Gelber RD, Coates AS, Goldhirsch A, Rae JM, Viale G. CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial. J Natl Cancer Inst. 2012 Mar 21; 104(6):441-51.
    View in: PubMed
  21. Furlong W, Rae C, Feeny D, Gelber RD, Laverdiere C, Michon B, Silverman L, Sallan S, Barr R. Health-related quality of life among children with acute lymphoblastic leukemia. Pediatr Blood Cancer. 2012 Oct; 59(4):717-24.
    View in: PubMed
  22. Baselga J, Bradbury I, Eidtmann H, Di Cosimo S, de Azambuja E, Aura C, Gómez H, Dinh P, Fauria K, Van Dooren V, Aktan G, Goldhirsch A, Chang TW, Horváth Z, Coccia-Portugal M, Domont J, Tseng LM, Kunz G, Sohn JH, Semiglazov V, Lerzo G, Palacova M, Probachai V, Pusztai L, Untch M, Gelber RD, Piccart-Gebhart M. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet. 2012 Feb 18; 379(9816):633-40.
    View in: PubMed
  23. Regan MM, Neven P, Giobbie-Hurder A, Goldhirsch A, Ejlertsen B, Mauriac L, Forbes JF, Smith I, Láng I, Wardley A, Rabaglio M, Price KN, Gelber RD, Coates AS, Thürlimann B. Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8·1 years median follow-up. Lancet Oncol. 2011 Nov; 12(12):1101-8.
    View in: PubMed
  24. Ejlertsen B, Aldridge J, Nielsen KV, Regan MM, Henriksen KL, Lykkesfeldt AE, Müller S, Gelber RD, Price KN, Rasmussen BB, Viale G, Mouridsen H. Prognostic and predictive role of ESR1 status for postmenopausal patients with endocrine-responsive early breast cancer in the Danish cohort of the BIG 1-98 trial. Ann Oncol. 2012 May; 23(5):1138-44.
    View in: PubMed
  25. Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thürlimann B, Senn HJ. Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol. 2011 Aug; 22(8):1736-47.
    View in: PubMed
  26. Pagani O, Partridge A, Korde L, Badve S, Bartlett J, Albain K, Gelber R, Goldhirsch A. Pregnancy after breast cancer: if you wish, ma'am. Breast Cancer Res Treat. 2011 Sep; 129(2):309-17.
    View in: PubMed
  27. Regan MM, Price KN, Giobbie-Hurder A, Thürlimann B, Gelber RD. Interpreting Breast International Group (BIG) 1-98: a randomized, double-blind, phase III trial comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with hormone receptor-positive, early breast cancer. Breast Cancer Res. 2011; 13(3):209.
    View in: PubMed
  28. Gianni L, Dafni U, Gelber RD, Azambuja E, Muehlbauer S, Goldhirsch A, Untch M, Smith I, Baselga J, Jackisch C, Cameron D, Mano M, Pedrini JL, Veronesi A, Mendiola C, Pluzanska A, Semiglazov V, Vrdoljak E, Eckart MJ, Shen Z, Skiadopoulos G, Procter M, Pritchard KI, Piccart-Gebhart MJ, Bell R. Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial. Lancet Oncol. 2011 Mar; 12(3):236-44.
    View in: PubMed
  29. Viale G, Regan MM, Dell'Orto P, Mastropasqua MG, Maiorano E, Rasmussen BB, MacGrogan G, Forbes JF, Paridaens RJ, Colleoni M, Láng I, Thürlimann B, Mouridsen H, Mauriac L, Gelber RD, Price KN, Goldhirsch A, Gusterson BA, Coates AS. Which patients benefit most from adjuvant aromatase inhibitors? Results using a composite measure of prognostic risk in the BIG 1-98 randomized trial. Ann Oncol. 2011 Oct; 22(10):2201-7.
    View in: PubMed
  30. Karlsson P, Sun Z, Braun D, Price KN, Castiglione-Gertsch M, Rabaglio M, Gelber RD, Crivellari D, Collins J, Murray E, Zaman K, Colleoni M, Gusterson BA, Viale G, Regan MM, Coates AS, Goldhirsch A. Long-term results of International Breast Cancer Study Group Trial VIII: adjuvant chemotherapy plus goserelin compared with either therapy alone for premenopausal patients with node-negative breast cancer. Ann Oncol. 2011 Oct; 22(10):2216-26.
    View in: PubMed
  31. Colleoni M, Giobbie-Hurder A, Regan MM, Thürlimann B, Mouridsen H, Mauriac L, Forbes JF, Paridaens R, Láng I, Smith I, Chirgwin J, Pienkowski T, Wardley A, Price KN, Gelber RD, Coates AS, Goldhirsch A. Analyses adjusting for selective crossover show improved overall survival with adjuvant letrozole compared with tamoxifen in the BIG 1-98 study. J Clin Oncol. 2011 Mar 20; 29(9):1117-24.
    View in: PubMed
  32. Aebi S, Sun Z, Braun D, Price KN, Castiglione-Gertsch M, Rabaglio M, Gelber RD, Crivellari D, Lindtner J, Snyder R, Karlsson P, Simoncini E, Gusterson BA, Viale G, Regan MM, Coates AS, Goldhirsch A. Differential efficacy of three cycles of CMF followed by tamoxifen in patients with ER-positive and ER-negative tumors: long-term follow up on IBCSG Trial IX. Ann Oncol. 2011 Sep; 22(9):1981-7.
    View in: PubMed
  33. Phillips KA, Aldridge J, Ribi K, Sun Z, Thompson A, Harvey V, Thürlimann B, Cardoso F, Pagani O, Coates AS, Goldhirsch A, Price KN, Gelber RD, Bernhard J. Cognitive function in postmenopausal breast cancer patients one year after completing adjuvant endocrine therapy with letrozole and/or tamoxifen in the BIG 1-98 trial. Breast Cancer Res Treat. 2011 Feb; 126(1):221-6.
    View in: PubMed
  34. Lazar AA, Cole BF, Bonetti M, Gelber RD. Evaluation of treatment-effect heterogeneity using biomarkers measured on a continuous scale: subpopulation treatment effect pattern plot. J Clin Oncol. 2010 Oct 10; 28(29):4539-44.
    View in: PubMed
  35. Gunnarsdóttir KA, Jensen MB, Zahrieh D, Gelber RD, Knoop A, Bonetti M, Mouridsen H, Ejlertsen B. CEF is superior to CMF for tumours with TOP2A aberrations: a Subpopulation Treatment Effect Pattern Plot (STEPP) analysis on Danish Breast Cancer Cooperative Group Study 89D. Breast Cancer Res Treat. 2010 Aug; 123(1):163-9.
    View in: PubMed
  36. Colleoni M, Cole BF, Viale G, Regan MM, Price KN, Maiorano E, Mastropasqua MG, Crivellari D, Gelber RD, Goldhirsch A, Coates AS, Gusterson BA. Classical cyclophosphamide, methotrexate, and fluorouracil chemotherapy is more effective in triple-negative, node-negative breast cancer: results from two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer. J Clin Oncol. 2010 Jun 20; 28(18):2966-73.
    View in: PubMed
  37. Phillips KA, Ribi K, Sun Z, Stephens A, Thompson A, Harvey V, Thürlimann B, Cardoso F, Pagani O, Coates AS, Goldhirsch A, Price KN, Gelber RD, Bernhard J. Cognitive function in postmenopausal women receiving adjuvant letrozole or tamoxifen for breast cancer in the BIG 1-98 randomized trial. Breast. 2010 Oct; 19(5):388-95.
    View in: PubMed
  38. Paridaens RJ, Gelber S, Cole BF, Gelber RD, Thürlimann B, Price KN, Holmberg SB, Crivellari D, Coates AS, Goldhirsch A. Adjuvant! Online estimation of chemotherapy effectiveness when added to ovarian function suppression plus tamoxifen for premenopausal women with estrogen-receptor-positive breast cancer. Breast Cancer Res Treat. 2010 Aug; 123(1):303-10.
    View in: PubMed
  39. de Azambuja E, McCaskill-Stevens W, Francis P, Quinaux E, Crown JP, Vicente M, Giuliani R, Nordenskjöld B, Gutiérez J, Andersson M, Vila MM, Jakesz R, Demol J, Dewar J, Santoro A, Lluch A, Olsen S, Gelber RD, Di Leo A, Piccart-Gebhart M. The effect of body mass index on overall and disease-free survival in node-positive breast cancer patients treated with docetaxel and doxorubicin-containing adjuvant chemotherapy: the experience of the BIG 02-98 trial. Breast Cancer Res Treat. 2010 Jan; 119(1):145-53.
    View in: PubMed
  40. Gelber RD, Gelber S. Facilitating consensus by examining patterns of treatment effects. Breast. 2009 Oct; 18 Suppl 3:S2-8.
    View in: PubMed
  41. Mouridsen H, Giobbie-Hurder A, Goldhirsch A, Thürlimann B, Paridaens R, Smith I, Mauriac L, Forbes J, Price KN, Regan MM, Gelber RD, Coates AS. Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer. N Engl J Med. 2009 Aug 20; 361(8):766-76.
    View in: PubMed
  42. Viale G, Giobbie-Hurder A, Gusterson BA, Maiorano E, Mastropasqua MG, Sonzogni A, Mallon E, Colleoni M, Castiglione-Gertsch M, Regan MM, Price KN, Brown RW, Golouh R, Crivellari D, Karlsson P, Ohlschlegel C, Gelber RD, Goldhirsch A, Coates AS. Adverse prognostic value of peritumoral vascular invasion: is it abrogated by adequate endocrine adjuvant therapy? Results from two International Breast Cancer Study Group randomized trials of chemoendocrine adjuvant therapy for early breast cancer. Ann Oncol. 2010 Feb; 21(2):245-54.
    View in: PubMed
  43. Desmedt C, Giobbie-Hurder A, Neven P, Paridaens R, Christiaens MR, Smeets A, Lallemand F, Haibe-Kains B, Viale G, Gelber RD, Piccart M, Sotiriou C. The Gene expression Grade Index: a potential predictor of relapse for endocrine-treated breast cancer patients in the BIG 1-98 trial. BMC Med Genomics. 2009; 2:40.
    View in: PubMed
  44. Goldhirsch A, Ingle JN, Gelber RD, Coates AS, Thürlimann B, Senn HJ. Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann Oncol. 2009 Aug; 20(8):1319-29.
    View in: PubMed
  45. Giobbie-Hurder A, Price KN, Gelber RD. Design, conduct, and analyses of Breast International Group (BIG) 1-98: a randomized, double-blind, phase-III study comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with receptor-positive, early breast cancer. Clin Trials. 2009 Jun; 6(3):272-87.
    View in: PubMed
  46. Grant CS, Ingle JN, Suman VJ, Dumesic DA, Wickerham DL, Gelber RD, Flynn PJ, Weir LM, Intra M, Jones WO, Perez EA, Hartmann LC. Menstrual cycle and surgical treatment of breast cancer: findings from the NCCTG N9431 study. J Clin Oncol. 2009 Aug 1; 27(22):3620-6.
    View in: PubMed
  47. Gelber RD, Aebi S. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med. 2009 May 28; 360(22):2367; author reply 2369-70.
    View in: PubMed
  48. Rabaglio M, Sun Z, Price KN, Castiglione-Gertsch M, Hawle H, Thürlimann B, Mouridsen H, Campone M, Forbes JF, Paridaens RJ, Colleoni M, Pienkowski T, Nogaret JM, Láng I, Smith I, Gelber RD, Goldhirsch A, Coates AS. Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial. Ann Oncol. 2009 Sep; 20(9):1489-98.
    View in: PubMed
  49. Colleoni M, Sun Z, Martinelli G, Basser RL, Coates AS, Gelber RD, Green MD, Peccatori F, Cinieri S, Aebi S, Viale G, Price KN, Goldhirsch A. The effect of endocrine responsiveness on high-risk breast cancer treated with dose-intensive chemotherapy: results of International Breast Cancer Study Group Trial 15-95 after prolonged follow-up. Ann Oncol. 2009 Aug; 20(8):1344-51.
    View in: PubMed
  50. Bonetti M, Zahrieh D, Cole BF, Gelber RD. A small sample study of the STEPP approach to assessing treatment-covariate interactions in survival data. Stat Med. 2009 Apr 15; 28(8):1255-68.
    View in: PubMed
  51. Dowsett M, Procter M, McCaskill-Stevens W, de Azambuja E, Dafni U, Rueschoff J, Jordan B, Dolci S, Abramovitz M, Stoss O, Viale G, Gelber RD, Piccart-Gebhart M, Leyland-Jones B. Disease-free survival according to degree of HER2 amplification for patients treated with adjuvant chemotherapy with or without 1 year of trastuzumab: the HERA Trial. J Clin Oncol. 2009 Jun 20; 27(18):2962-9.
    View in: PubMed
  52. Maiorano E, Regan MM, Viale G, Mastropasqua MG, Colleoni M, Castiglione-Gertsch M, Price KN, Gelber RD, Goldhirsch A, Coates AS. Prognostic and predictive impact of central necrosis and fibrosis in early breast cancer: results from two International Breast Cancer Study Group randomized trials of chemoendocrine adjuvant therapy. Breast Cancer Res Treat. 2010 May; 121(1):211-8.
    View in: PubMed
  53. Sun Z, Goldhirsch A, Price KN, Colleoni M, Ravaioli A, Simoncini E, Campbell I, Gelber RD, Towler M. Bone Quality Test (BQT) scores of fingernails in postmenopausal patients treated with adjuvant letrozole or tamoxifen for early breast cancer. Breast. 2009 Apr; 18(2):84-8.
    View in: PubMed
  54. Pagani O, Price KN, Gelber RD, Castiglione-Gertsch M, Holmberg SB, Lindtner J, Thürlimann B, Collins J, Fey MF, Coates AS, Goldhirsch A. Patterns of recurrence of early breast cancer according to estrogen receptor status: a therapeutic target for a quarter of a century. Breast Cancer Res Treat. 2009 Sep; 117(2):319-24.
    View in: PubMed
  55. Gianni L, Gelber S, Ravaioli A, Price KN, Panzini I, Fantini M, Castiglione-Gertsch M, Pagani O, Simoncini E, Gelber RD, Coates AS, Goldhirsch A. Second non-breast primary cancer following adjuvant therapy for early breast cancer: a report from the International Breast Cancer Study Group. Eur J Cancer. 2009 Mar; 45(4):561-71.
    View in: PubMed
  56. Viale G, Giobbie-Hurder A, Regan MM, Coates AS, Mastropasqua MG, Dell'Orto P, Maiorano E, MacGrogan G, Braye SG, Ohlschlegel C, Neven P, Orosz Z, Olszewski WP, Knox F, Thürlimann B, Price KN, Castiglione-Gertsch M, Gelber RD, Gusterson BA, Goldhirsch A. Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: results from Breast International Group Trial 1-98 comparing adjuvant tamoxifen with letrozole. J Clin Oncol. 2008 Dec 1; 26(34):5569-75.
    View in: PubMed
  57. Pagani O, Gelber S, Simoncini E, Castiglione-Gertsch M, Price KN, Gelber RD, Holmberg SB, Crivellari D, Collins J, Lindtner J, Thürlimann B, Fey MF, Murray E, Forbes JF, Coates AS, Goldhirsch A. Is adjuvant chemotherapy of benefit for postmenopausal women who receive endocrine treatment for highly endocrine-responsive, node-positive breast cancer? International Breast Cancer Study Group Trials VII and 12-93. Breast Cancer Res Treat. 2009 Aug; 116(3):491-500.
    View in: PubMed
  58. Colleoni M, Bagnardi V, Rotmensz N, Gelber RD, Viale G, Pruneri G, Veronesi P, Torrisi R, Cardillo A, Montagna E, Campagnoli E, Luini A, Intra M, Galimberti V, Scarano E, Peruzzotti G, Goldhirsch A. Increasing steroid hormone receptors expression defines breast cancer subtypes non responsive to preoperative chemotherapy. Breast Cancer Res Treat. 2009 Jul; 116(2):359-69.
    View in: PubMed
  59. Anderson JR, Cain KC, Gelber RD. Analysis of survival by tumor response and other comparisons of time-to-event by outcome variables. J Clin Oncol. 2008 Aug 20; 26(24):3913-5.
    View in: PubMed
  60. Bonetti M, Cole BF, Gelber RD. Another STEPP in the right direction. J Clin Oncol. 2008 Aug 1; 26(22):3813-4; author reply 3814-5.
    View in: PubMed
  61. Pestalozzi BC, Francis P, Quinaux E, Dolci S, Azambuja E, Gelber RD, Viale G, Balil A, Andersson M, Nordenskjöld B, Gnant M, Gutierrez J, Láng I, Crown JP, Piccart-Gebhart M. Is risk of central nervous system (CNS) relapse related to adjuvant taxane treatment in node-positive breast cancer? Results of the CNS substudy in the intergroup Phase III BIG 02-98 Trial. Ann Oncol. 2008 Nov; 19(11):1837-41.
    View in: PubMed
  62. Wapnir IL, Aebi S, Geyer CE, Zahrieh D, Gelber RD, Anderson SJ, Robidoux A, Bernhard J, Maibach R, Castiglione-Gertsch M, Coates AS, Piccart MJ, Clemons MJ, Costantino JP, Wolmark N. A randomized clinical trial of adjuvant chemotherapy for radically resected locoregional relapse of breast cancer: IBCSG 27-02, BIG 1-02, and NSABP B-37. Clin Breast Cancer. 2008 Jun; 8(3):287-92.
    View in: PubMed
  63. Pestalozzi BC, Zahrieh D, Mallon E, Gusterson BA, Price KN, Gelber RD, Holmberg SB, Lindtner J, Snyder R, Thürlimann B, Murray E, Viale G, Castiglione-Gertsch M, Coates AS, Goldhirsch A. Distinct clinical and prognostic features of infiltrating lobular carcinoma of the breast: combined results of 15 International Breast Cancer Study Group clinical trials. J Clin Oncol. 2008 Jun 20; 26(18):3006-14.
    View in: PubMed
  64. Gruber G, Cole BF, Castiglione-Gertsch M, Holmberg SB, Lindtner J, Golouh R, Collins J, Crivellari D, Thürlimann B, Simoncini E, Fey MF, Gelber RD, Coates AS, Price KN, Goldhirsch A, Viale G, Gusterson BA. Extracapsular tumor spread and the risk of local, axillary and supraclavicular recurrence in node-positive, premenopausal patients with breast cancer. Ann Oncol. 2008 Aug; 19(8):1393-401.
    View in: PubMed
  65. Viale G, Regan MM, Maiorano E, Mastropasqua MG, Golouh R, Perin T, Brown RW, Kovács A, Pillay K, Ohlschlegel C, Braye S, Grigolato P, Rusca T, Gelber RD, Castiglione-Gertsch M, Price KN, Goldhirsch A, Gusterson BA, Coates AS. Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: predictive value of centrally reviewed expression of estrogen and progesterone receptors--International Breast Cancer Study Group. J Clin Oncol. 2008 Mar 20; 26(9):1404-10.
    View in: PubMed
  66. Crivellari D, Sun Z, Coates AS, Price KN, Thürlimann B, Mouridsen H, Mauriac L, Forbes JF, Paridaens RJ, Castiglione-Gertsch M, Gelber RD, Colleoni M, Láng I, Del Mastro L, Gladieff L, Rabaglio M, Smith IE, Chirgwin JH, Goldhirsch A. Letrozole compared with tamoxifen for elderly patients with endocrine-responsive early breast cancer: the BIG 1-98 trial. J Clin Oncol. 2008 Apr 20; 26(12):1972-9.
    View in: PubMed
  67. Regan MM, Pagani O, Walley B, Torrisi R, Perez EA, Francis P, Fleming GF, Price KN, Thürlimann B, Maibach R, Castiglione-Gertsch M, Coates AS, Goldhirsch A, Gelber RD. Premenopausal endocrine-responsive early breast cancer: who receives chemotherapy? Ann Oncol. 2008 Jul; 19(7):1231-41.
    View in: PubMed
  68. Untch M, Gelber RD, Jackisch C, Procter M, Baselga J, Bell R, Cameron D, Bari M, Smith I, Leyland-Jones B, de Azambuja E, Wermuth P, Khasanov R, Feng-Yi F, Constantin C, Mayordomo JI, Su CH, Yu SY, Lluch A, Senkus-Konefka E, Price C, Haslbauer F, Suarez Sahui T, Srimuninnimit V, Colleoni M, Coates AS, Piccart-Gebhart MJ, Goldhirsch A. Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trial. Ann Oncol. 2008 Jun; 19(6):1090-6.
    View in: PubMed
  69. Thürlimann B, Price KN, Gelber RD, Holmberg SB, Crivellari D, Colleoni M, Collins J, Forbes JF, Castiglione-Gertsch M, Coates AS, Goldhirsch A. Is chemotherapy necessary for premenopausal women with lower-risk node-positive, endocrine responsive breast cancer? 10-year update of International Breast Cancer Study Group Trial 11-93. Breast Cancer Res Treat. 2009 Jan; 113(1):137-44.
    View in: PubMed
  70. Viale G, Regan MM, Mastropasqua MG, Maffini F, Maiorano E, Colleoni M, Price KN, Golouh R, Perin T, Brown RW, Kovács A, Pillay K, Ohlschlegel C, Gusterson BA, Castiglione-Gertsch M, Gelber RD, Goldhirsch A, Coates AS. Predictive value of tumor Ki-67 expression in two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer. J Natl Cancer Inst. 2008 Feb 6; 100(3):207-12.
    View in: PubMed
  71. Francis P, Crown J, Di Leo A, Buyse M, Balil A, Andersson M, Nordenskjöld B, Lang I, Jakesz R, Vorobiof D, Gutiérrez J, van Hazel G, Dolci S, Jamin S, Bendahmane B, Gelber RD, Goldhirsch A, Castiglione-Gertsch M, Piccart-Gebhart M. Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02-98 randomized trial. J Natl Cancer Inst. 2008 Jan 16; 100(2):121-33.
    View in: PubMed
  72. Clarke M, Coates AS, Darby SC, Davies C, Gelber RD, Godwin J, Goldhirsch A, Gray R, Peto R, Pritchard KI, Wood WC. Adjuvant chemotherapy in oestrogen-receptor-poor breast cancer: patient-level meta-analysis of randomised trials. Lancet. 2008 Jan 5; 371(9606):29-40.
    View in: PubMed
  73. Rasmussen BB, Regan MM, Lykkesfeldt AE, Dell'Orto P, Del Curto B, Henriksen KL, Mastropasqua MG, Price KN, Méry E, Lacroix-Triki M, Braye S, Altermatt HJ, Gelber RD, Castiglione-Gertsch M, Goldhirsch A, Gusterson BA, Thürlimann B, Coates AS, Viale G. Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial. Lancet Oncol. 2008 Jan; 9(1):23-8.
    View in: PubMed
  74. Bernhard J, Zahrieh D, Zhang JJ, Martinelli G, Basser R, Hürny C, Forbes JF, Aebi S, Yeo W, Thürlimann B, Green MD, Colleoni M, Gelber RD, Castiglione-Gertsch M, Price KN, Goldhirsch A, Coates AS. Quality of life and quality-adjusted survival (Q-TWiST) in patients receiving dose-intensive or standard dose chemotherapy for high-risk primary breast cancer. Br J Cancer. 2008 Jan 15; 98(1):25-33.
    View in: PubMed
  75. Mouridsen H, Keshaviah A, Coates AS, Rabaglio M, Castiglione-Gertsch M, Sun Z, Thürlimann B, Mauriac L, Forbes JF, Paridaens R, Gelber RD, Colleoni M, Smith I, Price KN, Goldhirsch A. Cardiovascular adverse events during adjuvant endocrine therapy for early breast cancer using letrozole or tamoxifen: safety analysis of BIG 1-98 trial. J Clin Oncol. 2007 Dec 20; 25(36):5715-22.
    View in: PubMed
  76. Colleoni M, Viale G, Zahrieh D, Bottiglieri L, Gelber RD, Veronesi P, Balduzzi A, Torrisi R, Luini A, Intra M, Dellapasqua S, Cardillo A, Ghisini R, Peruzzotti G, Goldhirsch A. Expression of ER, PgR, HER1, HER2, and response: a study of preoperative chemotherapy. Ann Oncol. 2008 Mar; 19(3):465-72.
    View in: PubMed
  77. Regan MM, Gelber RD. Using clinical trial data to tailor adjuvant treatments for individual patients. Breast. 2007 Dec; 16 Suppl 2:S98-104.
    View in: PubMed
  78. Viale G, Regan MM, Maiorano E, Mastropasqua MG, Dell'Orto P, Rasmussen BB, Raffoul J, Neven P, Orosz Z, Braye S, Ohlschlegel C, Thürlimann B, Gelber RD, Castiglione-Gertsch M, Price KN, Goldhirsch A, Gusterson BA, Coates AS. Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98. J Clin Oncol. 2007 Sep 1; 25(25):3846-52.
    View in: PubMed
  79. Suter TM, Procter M, van Veldhuisen DJ, Muscholl M, Bergh J, Carlomagno C, Perren T, Passalacqua R, Bighin C, Klijn JG, Ageev FT, Hitre E, Groetz J, Iwata H, Knap M, Gnant M, Muehlbauer S, Spence A, Gelber RD, Piccart-Gebhart MJ. Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial. J Clin Oncol. 2007 Sep 1; 25(25):3859-65.
    View in: PubMed
  80. Rocca A, Viale G, Gelber RD, Bottiglieri L, Gelber S, Pruneri G, Ghisini R, Balduzzi A, Pietri E, D'Alessandro C, Goldhirsch A, Colleoni M. Pathologic complete remission rate after cisplatin-based primary chemotherapy in breast cancer: correlation with p63 expression. Cancer Chemother Pharmacol. 2008 May; 61(6):965-71.
    View in: PubMed
  81. Goldhirsch A, Wood WC, Gelber RD, Coates AS, Thürlimann B, Senn HJ. Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol. 2007 Jul; 18(7):1133-44.
    View in: PubMed
  82. Newell ML, Huang S, Fiore S, Thorne C, Mandelbrot L, Sullivan JL, Maupin R, Delke I, Watts DH, Gelber RD, Cunningham CK. Characteristics and management of HIV-1-infected pregnant women enrolled in a randomised trial: differences between Europe and the USA. BMC Infect Dis. 2007; 7:60.
    View in: PubMed
  83. Hudis CA, Barlow WE, Costantino JP, Gray RJ, Pritchard KI, Chapman JA, Sparano JA, Hunsberger S, Enos RA, Gelber RD, Zujewski JA. Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system. J Clin Oncol. 2007 May 20; 25(15):2127-32.
    View in: PubMed
  84. Partridge A, Gelber S, Gelber RD, Castiglione-Gertsch M, Goldhirsch A, Winer E. Age of menopause among women who remain premenopausal following treatment for early breast cancer: long-term results from International Breast Cancer Study Group Trials V and VI. Eur J Cancer. 2007 Jul; 43(11):1646-53.
    View in: PubMed
  85. Jordan VC, Gelber RD. Problems with the progesterone receptor in practice? J Clin Oncol. 2007 May 20; 25(15):1957-9.
    View in: PubMed
  86. Effects of a treatment gap during adjuvant chemotherapy in node-positive breast cancer: results of International Breast Cancer Study Group (IBCSG) Trials 13-93 and 14-93. Ann Oncol. 2007 Jul; 18(7):1177-84.
    View in: PubMed
  87. Karlsson P, Cole BF, Price KN, Coates AS, Castiglione-Gertsch M, Gusterson BA, Murray E, Lindtner J, Collins JP, Holmberg SB, Fey MF, Thürlimann B, Crivellari D, Forbes JF, Gelber RD, Goldhirsch A, Wallgren A. The role of the number of uninvolved lymph nodes in predicting locoregional recurrence in breast cancer. J Clin Oncol. 2007 May 20; 25(15):2019-26.
    View in: PubMed
  88. Mauriac L, Keshaviah A, Debled M, Mouridsen H, Forbes JF, Thürlimann B, Paridaens R, Monnier A, Láng I, Wardley A, Nogaret JM, Gelber RD, Castiglione-Gertsch M, Price KN, Coates AS, Smith I, Viale G, Rabaglio M, Zabaznyi N, Goldhirsch A. Predictors of early relapse in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial. Ann Oncol. 2007 May; 18(5):859-67.
    View in: PubMed
  89. Keshaviah A, Dellapasqua S, Rotmensz N, Lindtner J, Crivellari D, Collins J, Colleoni M, Thürlimann B, Mendiola C, Aebi S, Price KN, Pagani O, Simoncini E, Castiglione Gertsch M, Gelber RD, Coates AS, Goldhirsch A. CA15-3 and alkaline phosphatase as predictors for breast cancer recurrence: a combined analysis of seven International Breast Cancer Study Group trials. Ann Oncol. 2007 Apr; 18(4):701-8.
    View in: PubMed
  90. Smith I, Procter M, Gelber RD, Guillaume S, Feyereislova A, Dowsett M, Goldhirsch A, Untch M, Mariani G, Baselga J, Kaufmann M, Cameron D, Bell R, Bergh J, Coleman R, Wardley A, Harbeck N, Lopez RI, Mallmann P, Gelmon K, Wilcken N, Wist E, Sánchez Rovira P, Piccart-Gebhart MJ. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet. 2007 Jan 6; 369(9555):29-36.
    View in: PubMed
  91. Coates AS, Keshaviah A, Thürlimann B, Mouridsen H, Mauriac L, Forbes JF, Paridaens R, Castiglione-Gertsch M, Gelber RD, Colleoni M, Láng I, Del Mastro L, Smith I, Chirgwin J, Nogaret JM, Pienkowski T, Wardley A, Jakobsen EH, Price KN, Goldhirsch A. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. J Clin Oncol. 2007 Feb 10; 25(5):486-92.
    View in: PubMed
  92. Bernhard J, Zahrieh D, Castiglione-Gertsch M, Hürny C, Gelber RD, Forbes JF, Murray E, Collins J, Aebi S, Thürlimann B, Price KN, Goldhirsch A, Coates AS. Adjuvant chemotherapy followed by goserelin compared with either modality alone: the impact on amenorrhea, hot flashes, and quality of life in premenopausal patients--the International Breast Cancer Study Group Trial VIII. J Clin Oncol. 2007 Jan 20; 25(3):263-70.
    View in: PubMed
  93. Regan MM, Viale G, Mastropasqua MG, Maiorano E, Golouh R, Carbone A, Brown B, Suurküla M, Langman G, Mazzucchelli L, Braye S, Grigolato P, Gelber RD, Castiglione-Gertsch M, Price KN, Coates AS, Goldhirsch A, Gusterson B. Re-evaluating adjuvant breast cancer trials: assessing hormone receptor status by immunohistochemical versus extraction assays. J Natl Cancer Inst. 2006 Nov 1; 98(21):1571-81.
    View in: PubMed
  94. Goldhirsch A, Coates AS, Gelber RD, Glick JH, Thürlimann B, Senn HJ. First--select the target: better choice of adjuvant treatments for breast cancer patients. Ann Oncol. 2006 Dec; 17(12):1772-6.
    View in: PubMed
  95. Moghrabi A, Levy DE, Asselin B, Barr R, Clavell L, Hurwitz C, Samson Y, Schorin M, Dalton VK, Lipshultz SE, Neuberg DS, Gelber RD, Cohen HJ, Sallan SE, Silverman LB. Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95-01 for children with acute lymphoblastic leukemia. Blood. 2007 Feb 1; 109(3):896-904.
    View in: PubMed
  96. Pestalozzi BC, Zahrieh D, Price KN, Holmberg SB, Lindtner J, Collins J, Crivellari D, Fey MF, Murray E, Pagani O, Simoncini E, Castiglione-Gertsch M, Gelber RD, Coates AS, Goldhirsch A. Identifying breast cancer patients at risk for Central Nervous System (CNS) metastases in trials of the International Breast Cancer Study Group (IBCSG). Ann Oncol. 2006 Jun; 17(6):935-44.
    View in: PubMed
  97. Tamoxifen after adjuvant chemotherapy for premenopausal women with lymph node-positive breast cancer: International Breast Cancer Study Group Trial 13-93. J Clin Oncol. 2006 Mar 20; 24(9):1332-41.
    View in: PubMed
  98. Gianni L, Panzini I, Li S, Gelber RD, Collins J, Holmberg SB, Crivellari D, Castiglione-Gertsch M, Goldhirsch A, Coates AS, Ravaioli A. Ocular toxicity during adjuvant chemoendocrine therapy for early breast cancer: results from International Breast Cancer Study Group trials. Cancer. 2006 Feb 1; 106(3):505-13.
    View in: PubMed
  99. Fitzmaurice GM, Lipsitz SR, Ibrahim JG, Gelber R, Lipshultz S. Estimation in regression models for longitudinal binary data with outcome-dependent follow-up. Biostatistics. 2006 Jul; 7(3):469-85.
    View in: PubMed
  100. Multicycle dose-intensive chemotherapy for women with high-risk primary breast cancer: results of International Breast Cancer Study Group Trial 15-95. J Clin Oncol. 2006 Jan 20; 24(3):370-8.
    View in: PubMed
  101. Thürlimann B, Keshaviah A, Coates AS, Mouridsen H, Mauriac L, Forbes JF, Paridaens R, Castiglione-Gertsch M, Gelber RD, Rabaglio M, Smith I, Wardley A, Wardly A, Price KN, Goldhirsch A. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med. 2005 Dec 29; 353(26):2747-57.
    View in: PubMed
  102. Randomized trial comparing axillary clearance versus no axillary clearance in older patients with breast cancer: first results of International Breast Cancer Study Group Trial 10-93. J Clin Oncol. 2006 Jan 20; 24(3):337-44.
    View in: PubMed
  103. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, Gianni L, Baselga J, Bell R, Jackisch C, Cameron D, Dowsett M, Barrios CH, Steger G, Huang CS, Andersson M, Inbar M, Lichinitser M, Láng I, Nitz U, Iwata H, Thomssen C, Lohrisch C, Suter TM, Rüschoff J, Suto T, Greatorex V, Ward C, Straehle C, McFadden E, Dolci MS, Gelber RD. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005 Oct 20; 353(16):1659-72.
    View in: PubMed
  104. Gruber G, Bonetti M, Nasi ML, Price KN, Castiglione-Gertsch M, Rudenstam CM, Holmberg SB, Lindtner J, Golouh R, Collins J, Crivellari D, Carbone A, Thürlimann B, Simoncini E, Fey MF, Gelber RD, Coates AS, Goldhirsch A. Prognostic value of extracapsular tumor spread for locoregional control in premenopausal patients with node-positive breast cancer treated with classical cyclophosphamide, methotrexate, and fluorouracil: long-term observations from International Breast Cancer Study Group Trial VI. J Clin Oncol. 2005 Oct 1; 23(28):7089-97.
    View in: PubMed
  105. Regan MM, Gelber RD. Predicting response to systemic treatments: learning from the past to plan for the future. Breast. 2005 Dec; 14(6):582-93.
    View in: PubMed
  106. Goldhirsch A, Glick JH, Gelber RD, Coates AS, Thürlimann B, Senn HJ. Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005. Ann Oncol. 2005 Oct; 16(10):1569-83.
    View in: PubMed
  107. Goldhirsch A, Gelber RD, Coates AS. What are the long-term effects of chemotherapy and hormonal therapy for early breast cancer? Nat Clin Pract Oncol. 2005 Sep; 2(9):440-1.
    View in: PubMed
  108. Colleoni M, Li S, Gelber RD, Price KN, Coates AS, Castiglione-Gertsch M, Goldhirsch A. Relation between chemotherapy dose, oestrogen receptor expression, and body-mass index. Lancet. 2005 Sep 24-30; 366(9491):1108-10.
    View in: PubMed
  109. Cole BF, Bonetti M, Zaslavsky AM, Gelber RD. A multistate Markov chain model for longitudinal, categorical quality-of-life data subject to non-ignorable missingness. Stat Med. 2005 Aug 15; 24(15):2317-34.
    View in: PubMed
  110. Goldhirsch A, Gelber RD, Viale G, Colleoni M, Coates AS. Prediction of cancer outcome with microarrays. Lancet. 2005 May 14-20; 365(9472):1685-6; author reply 1686.
    View in: PubMed
  111. Lipshultz SE, Lipsitz SR, Sallan SE, Dalton VM, Mone SM, Gelber RD, Colan SD. Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia. J Clin Oncol. 2005 Apr 20; 23(12):2629-36.
    View in: PubMed
  112. Colleoni M, Li S, Gelber RD, Coates AS, Castiglione-Gertsch M, Price KN, Lindtner J, Rudenstam CM, Crivellari D, Collins J, Pagani O, Simoncini E, Thürlimann B, Murray E, Forbes J, Erzen D, Holmberg S, Veronesi A, Goldhirsch A. Timing of CMF chemotherapy in combination with tamoxifen in postmenopausal women with breast cancer: role of endocrine responsiveness of the tumor. Ann Oncol. 2005 May; 16(5):716-25.
    View in: PubMed
  113. Dellapasqua S, Colleoni M, Gelber RD, Goldhirsch A. Adjuvant endocrine therapy for premenopausal women with early breast cancer. J Clin Oncol. 2005 Mar 10; 23(8):1736-50.
    View in: PubMed
  114. Colleoni M, Zahrieh D, Gelber RD, Holmberg SB, Mattsson JE, Rudenstam CM, Lindtner J, Erzen D, Snyder R, Collins J, Fey MF, Thürlimann B, Crivellari D, Murray E, Mendiola C, Pagani O, Castiglione-Gertsch M, Coates AS, Price K, Goldhirsch A. Site of primary tumor has a prognostic role in operable breast cancer: the international breast cancer study group experience. J Clin Oncol. 2005 Mar 1; 23(7):1390-400.
    View in: PubMed
  115. Toremifene and tamoxifen are equally effective for early-stage breast cancer: first results of International Breast Cancer Study Group Trials 12-93 and 14-93. Ann Oncol. 2004 Dec; 15(12):1749-59.
    View in: PubMed
  116. Goldhirsch A, Gelber RD. Life with consequences of breast cancer: pregnancy during and after endocrine therapies. Breast. 2004 Dec; 13(6):443-5.
    View in: PubMed
  117. Bernhard J, Zahrieh D, Coates AS, Gelber RD, Castiglione-Gertsch M, Murray E, Forbes JF, Perey L, Collins J, Snyder R, Rudenstam CM, Crivellari D, Veronesi A, Thürlimann B, Fey MF, Price KN, Goldhirsch A, Hürny C. Quantifying trade-offs: quality of life and quality-adjusted survival in a randomised trial of chemotherapy in postmenopausal patients with lymph node-negative breast cancer. Br J Cancer. 2004 Nov 29; 91(11):1893-901.
    View in: PubMed
  118. Winer EP, Hudis C, Burstein HJ, Wolff AC, Pritchard KI, Ingle JN, Chlebowski RT, Gelber R, Edge SB, Gralow J, Cobleigh MA, Mamounas EP, Goldstein LJ, Whelan TJ, Powles TJ, Bryant J, Perkins C, Perotti J, Braun S, Langer AS, Browman GP, Somerfield MR. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J Clin Oncol. 2005 Jan 20; 23(3):619-29.
    View in: PubMed
  119. Colleoni M, Viale G, Zahrieh D, Pruneri G, Gentilini O, Veronesi P, Gelber RD, Curigliano G, Torrisi R, Luini A, Intra M, Galimberti V, Renne G, Nolè F, Peruzzotti G, Goldhirsch A. Chemotherapy is more effective in patients with breast cancer not expressing steroid hormone receptors: a study of preoperative treatment. Clin Cancer Res. 2004 Oct 1; 10(19):6622-8.
    View in: PubMed
  120. Lipshultz SE, Rifai N, Dalton VM, Levy DE, Silverman LB, Lipsitz SR, Colan SD, Asselin BL, Barr RD, Clavell LA, Hurwitz CA, Moghrabi A, Samson Y, Schorin MA, Gelber RD, Sallan SE. The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia. N Engl J Med. 2004 Jul 8; 351(2):145-53.
    View in: PubMed
  121. Cunningham CK, Balasubramanian R, Delke I, Maupin R, Mofenson L, Dorenbaum A, Sullivan JL, Gonzalez-Garcia A, Thorpe E, Rathore M, Gelber RD. The impact of race/ethnicity on mother-to-child HIV transmission in the United States in Pediatric AIDS Clinical Trials Group Protocol 316. J Acquir Immune Defic Syndr. 2004 Jul 1; 36(3):800-7.
    View in: PubMed
  122. Bonetti M, Gelber RD. Patterns of treatment effects in subsets of patients in clinical trials. Biostatistics. 2004 Jul; 5(3):465-81.
    View in: PubMed
  123. Waber DP, Silverman LB, Catania L, Mautz W, Rue M, Gelber RD, Levy DE, Goldwasser MA, Adams H, Dufresne A, Metzger V, Romero I, Tarbell NJ, Dalton VK, Sallan SE. Outcomes of a randomized trial of hyperfractionated cranial radiation therapy for treatment of high-risk acute lymphoblastic leukemia: therapeutic efficacy and neurotoxicity. J Clin Oncol. 2004 Jul 1; 22(13):2701-7.
    View in: PubMed
  124. Berclaz G, Li S, Price KN, Coates AS, Castiglione-Gertsch M, Rudenstam CM, Holmberg SB, Lindtner J, Erien D, Collins J, Snyder R, Thürlimann B, Fey MF, Mendiola C, Werner ID, Simoncini E, Crivellari D, Gelber RD, Goldhirsch A. Body mass index as a prognostic feature in operable breast cancer: the International Breast Cancer Study Group experience. Ann Oncol. 2004 Jun; 15(6):875-84.
    View in: PubMed
  125. Cole BF, Gelber RD, Gelber S, Mukhopadhyay P. A quality-adjusted survival (Q-TWiST) model for evaluating treatments for advanced stage cancer. J Biopharm Stat. 2004 Feb; 14(1):111-24.
    View in: PubMed
  126. Colleoni M, Rotmensz N, Martinelli G, Gelber R, Coates A, Goldhirsch A. Lesson learned from high-dose chemotherapy for high-risk breast cancer (What you see is what you mean). Ann Oncol. 2004 Feb; 15(2):355-6.
    View in: PubMed
  127. Watts DH, Balasubramanian R, Maupin RT, Delke I, Dorenbaum A, Fiore S, Newell ML, Delfraissy JF, Gelber RD, Mofenson LM, Culnane M, Cunningham CK. Maternal toxicity and pregnancy complications in human immunodeficiency virus-infected women receiving antiretroviral therapy: PACTG 316. Am J Obstet Gynecol. 2004 Feb; 190(2):506-16.
    View in: PubMed
  128. Adjuvant chemotherapy followed by goserelin versus either modality alone for premenopausal lymph node-negative breast cancer: a randomized trial. J Natl Cancer Inst. 2003 Dec 17; 95(24):1833-46.
    View in: PubMed
  129. Crivellari D, Price K, Gelber RD, Castiglione-Gertsch M, Rudenstam CM, Lindtner J, Fey MF, Senn HJ, Coates AS, Collins J, Goldhirsch A. Adjuvant endocrine therapy compared with no systemic therapy for elderly women with early breast cancer: 21-year results of International Breast Cancer Study Group Trial IV. J Clin Oncol. 2003 Dec 15; 21(24):4517-23.
    View in: PubMed
  130. Senn HJ, Thürlimann B, Goldhirsch A, Wood WC, Gelber RD, Coates AS. Comments on the St. Gallen Consensus 2003 on the Primary Therapy of Early Breast Cancer. Breast. 2003 Dec; 12(6):569-82.
    View in: PubMed
  131. Gelber RD, Bonetti M, Castiglione-Gertsch M, Coates AS, Goldhirsch A. Tailoring adjuvant treatments for the individual breast cancer patient. Breast. 2003 Dec; 12(6):558-68.
    View in: PubMed
  132. Colleoni M, Zahrieh D, Gelber RD, Viale G, Luini A, Veronesi P, Intra M, Galimberti V, Renne G, Goldhirsch A, Zarieh D. Preoperative systemic treatment: prediction of responsiveness. Breast. 2003 Dec; 12(6):538-42.
    View in: PubMed
  133. Goldberg JM, Silverman LB, Levy DE, Dalton VK, Gelber RD, Lehmann L, Cohen HJ, Sallan SE, Asselin BL. Childhood T-cell acute lymphoblastic leukemia: the Dana-Farber Cancer Institute acute lymphoblastic leukemia consortium experience. J Clin Oncol. 2003 Oct 1; 21(19):3616-22.
    View in: PubMed
  134. Goldhirsch A, Colleoni M, Domenighetti G, Gelber RD. Systemic treatments for women with breast cancer: outcome with relation to screening for the disease. Ann Oncol. 2003 Aug; 14(8):1212-4.
    View in: PubMed
  135. Dalton VK, Rue M, Silverman LB, Gelber RD, Asselin BL, Barr RD, Clavell LA, Hurwitz CA, Moghrabi A, Samson Y, Schorin M, Tarbell NJ, Sallan SE, Cohen LE. Height and weight in children treated for acute lymphoblastic leukemia: relationship to CNS treatment. J Clin Oncol. 2003 Aug 1; 21(15):2953-60.
    View in: PubMed
  136. Goldhirsch A, Wood WC, Gelber RD, Coates AS, Thürlimann B, Senn HJ. Meeting highlights: updated international expert consensus on the primary therapy of early breast cancer. J Clin Oncol. 2003 Sep 1; 21(17):3357-65.
    View in: PubMed
  137. Mirochnick M, Dorenbaum A, Blanchard S, Cunningham CK, Gelber RD, Mofenson L, Culnane M, Sullivan JL. Predose infant nevirapine concentration with the two-dose intrapartum neonatal nevirapine regimen: association with timing of maternal intrapartum nevirapine dose. J Acquir Immune Defic Syndr. 2003 Jun 1; 33(2):153-6.
    View in: PubMed
  138. Winer EP, Hudis C, Burstein HJ, Bryant J, Chlebowski RT, Ingle JN, Edge SB, Mamounas EP, Gelber R, Gralow J, Goldstein LJ, Pritchard KI, Braun S, Cobleigh MA, Langer AS, Perotti J, Powles TJ, Whelan TJ, Browman GP. American Society of Clinical Oncology technology assessment working group update: use of aromatase inhibitors in the adjuvant setting. J Clin Oncol. 2003 Jul 1; 21(13):2597-9.
    View in: PubMed
  139. Spataro VJ, Litman H, Viale G, Maffini F, Masullo M, Golouh R, Martinez-Tello FJ, Grigolato P, Shilkin KB, Gusterson BA, Castiglione-Gertsch M, Price K, Lindtner J, Cortés-Funes H, Simoncini E, Byrne MJ, Collins J, Gelber RD, Coates AS, Goldhirsch A. Decreased immunoreactivity for p27 protein in patients with early-stage breast carcinoma is correlated with HER-2/neu overexpression and with benefit from one course of perioperative chemotherapy in patients with negative lymph node status: results from International Breast Cancer Study Group Trial V. Cancer. 2003 Apr 1; 97(7):1591-600.
    View in: PubMed
  140. Wallgren A, Bonetti M, Gelber RD, Goldhirsch A, Castiglione-Gertsch M, Holmberg SB, Lindtner J, Thürlimann B, Fey M, Werner ID, Forbes JF, Price K, Coates AS, Collins J. Risk factors for locoregional recurrence among breast cancer patients: results from International Breast Cancer Study Group Trials I through VII. J Clin Oncol. 2003 Apr 1; 21(7):1205-13.
    View in: PubMed
  141. Trihia H, Murray S, Price K, Gelber RD, Golouh R, Goldhirsch A, Coates AS, Collins J, Castiglione-Gertsch M, Gusterson BA. Ki-67 expression in breast carcinoma: its association with grading systems, clinical parameters, and other prognostic factors--a surrogate marker? Cancer. 2003 Mar 1; 97(5):1321-31.
    View in: PubMed
  142. Lipshultz SE, Lipsitz SR, Sallan SE, Simbre VC, Shaikh SL, Mone SM, Gelber RD, Colan SD. Long-term enalapril therapy for left ventricular dysfunction in doxorubicin-treated survivors of childhood cancer. J Clin Oncol. 2002 Dec 1; 20(23):4517-22.
    View in: PubMed
  143. Lipsitz SR, Fitzmaurice GM, Ibrahim JG, Gelber R, Lipshultz S. Parameter estimation in longitudinal studies with outcome-dependent follow-up. Biometrics. 2002 Sep; 58(3):621-30.
    View in: PubMed
  144. Coates A, Goldhirsch A, Gelber R. Overhauling the breast cancer overview: are subsets subversive? Lancet Oncol. 2002 Sep; 3(9):525-6.
    View in: PubMed
  145. Mirochnick M, Dorenbaum A, Holland D, Cunningham-Schrader B, Cunningham C, Gelber R, Mofenson L, Culnane M, Connor J, Sullivan JL. Concentrations of protease inhibitors in cord blood after in utero exposure. Pediatr Infect Dis J. 2002 Sep; 21(9):835-8.
    View in: PubMed
  146. Dorenbaum A, Cunningham CK, Gelber RD, Culnane M, Mofenson L, Britto P, Rekacewicz C, Newell ML, Delfraissy JF, Cunningham-Schrader B, Mirochnick M, Sullivan JL. Two-dose intrapartum/newborn nevirapine and standard antiretroviral therapy to reduce perinatal HIV transmission: a randomized trial. JAMA. 2002 Jul 10; 288(2):189-98.
    View in: PubMed
  147. Cunningham CK, Chaix ML, Rekacewicz C, Britto P, Rouzioux C, Gelber RD, Dorenbaum A, Delfraissy JF, Bazin B, Mofenson L, Sullivan JL. Development of resistance mutations in women receiving standard antiretroviral therapy who received intrapartum nevirapine to prevent perinatal human immunodeficiency virus type 1 transmission: a substudy of pediatric AIDS clinical trials group protocol 316. J Infect Dis. 2002 Jul 15; 186(2):181-8.
    View in: PubMed
  148. Colleoni M, Litman HJ, Castiglione-Gertsch M, Sauerbrei W, Gelber RD, Bonetti M, Coates AS, Schumacher M, Bastert G, Rudenstam CM, Schmoor C, Lindtner J, Collins J, Thürlimann B, Holmberg SB, Crivellari D, Beyerle C, Neumann RL, Goldhirsch A. Duration of adjuvant chemotherapy for breast cancer: a joint analysis of two randomised trials investigating three versus six courses of CMF. Br J Cancer. 2002 Jun 5; 86(11):1705-14.
    View in: PubMed
  149. Earle CC, Neumann PJ, Gelber RD, Weinstein MC, Weeks JC. Impact of referral patterns on the use of chemotherapy for lung cancer. J Clin Oncol. 2002 Apr 1; 20(7):1786-92.
    View in: PubMed
  150. Lipshultz SE, Giantris AL, Lipsitz SR, Kimball Dalton V, Asselin BL, Barr RD, Clavell LA, Hurwitz CA, Moghrabi A, Samson Y, Schorin MA, Gelber RD, Sallan SE, Colan SD. Doxorubicin administration by continuous infusion is not cardioprotective: the Dana-Farber 91-01 Acute Lymphoblastic Leukemia protocol. J Clin Oncol. 2002 Mar 15; 20(6):1677-82.
    View in: PubMed
  151. LeClerc JM, Billett AL, Gelber RD, Dalton V, Tarbell N, Lipton JM, Barr R, Clavell LA, Asselin B, Hurwitz C, Schorin M, Lipshultz SE, Declerck L, Silverman LB, Cohen HJ, Sallan SE. Treatment of childhood acute lymphoblastic leukemia: results of Dana-Farber ALL Consortium Protocol 87-01. J Clin Oncol. 2002 Jan 1; 20(1):237-46.
    View in: PubMed
  152. Goldhirsch A, Colleoni M, Gelber RD. Endocrine therapy of breast cancer. Ann Oncol. 2002; 13 Suppl 4:61-8.
    View in: PubMed
  153. Colleoni M, Gelber S, Coates AS, Castiglione-Gertsch M, Gelber RD, Price K, Rudenstam CM, Lindtner J, Collins J, Thürlimann B, Holmberg SB, Cortes-Funes H, Simoncini E, Murray E, Fey M, Goldhirsch A. Influence of endocrine-related factors on response to perioperative chemotherapy for patients with node-negative breast cancer. J Clin Oncol. 2001 Nov 1; 19(21):4141-9.
    View in: PubMed
  154. Goldhirsch A, Glick JH, Gelber RD, Coates AS, Senn HJ. Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer. Seventh International Conference on Adjuvant Therapy of Primary Breast Cancer. J Clin Oncol. 2001 Sep 15; 19(18):3817-27.
    View in: PubMed
  155. Cole BF, Gelber RD, Gelber S, Coates AS, Goldhirsch A. Polychemotherapy for early breast cancer: an overview of the randomised clinical trials with quality-adjusted survival analysis. Lancet. 2001 Jul 28; 358(9278):277-86.
    View in: PubMed
  156. Waber DP, Shapiro BL, Carpentieri SC, Gelber RD, Zou G, Dufresne A, Romero I, Tarbell NJ, Silverman LB, Sallan SE. Excellent therapeutic efficacy and minimal late neurotoxicity in children treated with 18 grays of cranial radiation therapy for high-risk acute lymphoblastic leukemia: a 7-year follow-up study of the Dana-Farber Cancer Institute Consortium Protocol 87-01. Cancer. 2001 Jul 1; 92(1):15-22.
    View in: PubMed
  157. Strauss AJ, Su JT, Dalton VM, Gelber RD, Sallan SE, Silverman LB. Bony morbidity in children treated for acute lymphoblastic leukemia. J Clin Oncol. 2001 Jun 15; 19(12):3066-72.
    View in: PubMed
  158. Fine JP, Gelber RD. Joint regression analysis of survival and quality-adjusted survival. Biometrics. 2001 Jun; 57(2):376-82.
    View in: PubMed
  159. Gelber S, Coates AS, Goldhirsch A, Castiglione-Gertsch M, Marini G, Lindtner J, Edelmann DZ, Gudgeon A, Harvey V, Gelber RD. Effect of pregnancy on overall survival after the diagnosis of early-stage breast cancer. J Clin Oncol. 2001 Mar 15; 19(6):1671-5.
    View in: PubMed
  160. Silverman LB, Gelber RD, Dalton VK, Asselin BL, Barr RD, Clavell LA, Hurwitz CA, Moghrabi A, Samson Y, Schorin MA, Arkin S, Declerck L, Cohen HJ, Sallan SE. Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01. Blood. 2001 Mar 1; 97(5):1211-8.
    View in: PubMed
  161. Schwartz CL, Thompson EB, Gelber RD, Young ML, Chilton D, Cohen HJ, Sallan SE. Improved response with higher corticosteroid dose in children with acute lymphoblastic leukemia. J Clin Oncol. 2001 Feb 15; 19(4):1040-6.
    View in: PubMed
  162. Earle CC, Tsai JS, Gelber RD, Weinstein MC, Neumann PJ, Weeks JC. Effectiveness of chemotherapy for advanced lung cancer in the elderly: instrumental variable and propensity analysis. J Clin Oncol. 2001 Feb 15; 19(4):1064-70.
    View in: PubMed
  163. Goldhirsch A, Gelber RD, Yothers G, Gray RJ, Green S, Bryant J, Gelber S, Castiglione-Gertsch M, Coates AS. Adjuvant therapy for very young women with breast cancer: need for tailored treatments. J Natl Cancer Inst Monogr. 2001; (30):44-51.
    View in: PubMed
  164. Kitchen PR, Smith TH, Henderson MA, Goldhirsch A, Castiglione-Gertsch M, Coates AS, Gusterson B, Brown RW, Gelber RD, Collins JP. Tubular carcinoma of the breast: prognosis and response to adjuvant systemic therapy. ANZ J Surg. 2001 Jan; 71(1):27-31.
    View in: PubMed
  165. Silverman LB, Declerck L, Gelber RD, Dalton VK, Asselin BL, Barr RD, Clavell LA, Hurwitz CA, Moghrabi A, Samson Y, Schorin MA, Lipton JM, Cohen HJ, Sallan SE. Results of Dana-Farber Cancer Institute Consortium protocols for children with newly diagnosed acute lymphoblastic leukemia (1981-1995). Leukemia. 2000 Dec; 14(12):2247-56.
    View in: PubMed
  166. Colleoni M, O'Neill A, Goldhirsch A, Gelber RD, Bonetti M, Thürlimann B, Price KN, Castiglione-Gertsch M, Coates AS, Lindtner J, Collins J, Senn HJ, Cavalli F, Forbes J, Gudgeon A, Simoncini E, Cortes-Funes H, Veronesi A, Fey M, Rudenstam CM. Identifying breast cancer patients at high risk for bone metastases. J Clin Oncol. 2000 Dec 1; 18(23):3925-35.
    View in: PubMed
  167. Coates AS, Hürny C, Peterson HF, Bernhard J, Castiglione-Gertsch M, Gelber RD, Goldhirsch A. Quality-of-life scores predict outcome in metastatic but not early breast cancer. International Breast Cancer Study Group. J Clin Oncol. 2000 Nov 15; 18(22):3768-74.
    View in: PubMed
  168. Bonetti M, Gelber RD. A graphical method to assess treatment-covariate interactions using the Cox model on subsets of the data. Stat Med. 2000 Oct 15; 19(19):2595-609.
    View in: PubMed
  169. Goldhirsch A, Francis P, Castiglione-Gertsch M, Gelber RD, Coates AS. Taxanes as adjuvant for breast cancer. Lancet. 2000 Aug 5; 356(9228):507-8.
    View in: PubMed
  170. Aebi S, Gelber S, Castiglione-Gertsch M, Gelber RD, Collins J, Thürlimann B, Rudenstam CM, Lindtner J, Crivellari D, Cortes-Funes H, Simoncini E, Werner ID, Coates AS, Goldhirsch A. Is chemotherapy alone adequate for young women with oestrogen-receptor-positive breast cancer? Lancet. 2000 May 27; 355(9218):1869-74.
    View in: PubMed
  171. Earle CC, Venditti LN, Neumann PJ, Gelber RD, Weinstein MC, Potosky AL, Weeks JC. Who gets chemotherapy for metastatic lung cancer? Chest. 2000 May; 117(5):1239-46.
    View in: PubMed
  172. Hurwitz CA, Silverman LB, Schorin MA, Clavell LA, Dalton VK, Glick KM, Gelber RD, Sallan SE. Substituting dexamethasone for prednisone complicates remission induction in children with acute lymphoblastic leukemia. Cancer. 2000 Apr 15; 88(8):1964-9.
    View in: PubMed
  173. Crivellari D, Bonetti M, Castiglione-Gertsch M, Gelber RD, Rudenstam CM, Thürlimann B, Price KN, Coates AS, Hürny C, Bernhard J, Lindtner J, Collins J, Senn HJ, Cavalli F, Forbes J, Gudgeon A, Simoncini E, Cortes-Funes H, Veronesi A, Fey M, Goldhirsch A. Burdens and benefits of adjuvant cyclophosphamide, methotrexate, and fluorouracil and tamoxifen for elderly patients with breast cancer: the International Breast Cancer Study Group Trial VII. J Clin Oncol. 2000 Apr; 18(7):1412-22.
    View in: PubMed
  174. Castiglione-Gertsch M, Gelber RD, O'Neill A, Coates AS, Goldhirsch A. Systemic adjuvant treatment for premenopausal node-negative breast cancer. The International Breast Cancer Study Group. Eur J Cancer. 2000 Mar; 36(4):549-50.
    View in: PubMed
  175. Colleoni M, Bonetti M, Coates AS, Castiglione-Gertsch M, Gelber RD, Price K, Rudenstam CM, Lindtner J, Collins J, Thürlimann B, Holmberg S, Veronesi A, Marini G, Goldhirsch A. Early start of adjuvant chemotherapy may improve treatment outcome for premenopausal breast cancer patients with tumors not expressing estrogen receptors. The International Breast Cancer Study Group. J Clin Oncol. 2000 Feb; 18(3):584-90.
    View in: PubMed
  176. Cote RJ, Peterson HF, Chaiwun B, Gelber RD, Goldhirsch A, Castiglione-Gertsch M, Gusterson B, Neville AM. Role of immunohistochemical detection of lymph-node metastases in management of breast cancer. International Breast Cancer Study Group. Lancet. 1999 Sep 11; 354(9182):896-900.
    View in: PubMed
  177. Gelber RD, Shapiro DE. Mode of delivery and the risk of vertical transmission of HIV-1. N Engl J Med. 1999 Jul 15; 341(3):206-7.
    View in: PubMed
  178. Colleoni M, Price KN, Castiglione-Gertsch M, Gelber RD, Coates AS, Goldhirsch A. Mortality during adjuvant treatment of early breast cancer with cyclophosphamide, methotrexate, and fluorouracil. International Breast Cancer Study Group. Lancet. 1999 Jul 10; 354(9173):130-1.
    View in: PubMed
  179. Parsons SK, Gelber S, Cole BF, Ravindranath Y, Ogden A, Yeager AM, Chang M, Shuster J, Weinstein HJ, Gelber RD. Quality-adjusted survival after treatment for acute myeloid leukemia in childhood: A Q-TWiST analysis of the Pediatric Oncology Group Study 8821. J Clin Oncol. 1999 Jul; 17(7):2144-52.
    View in: PubMed
  180. Silverman LB, Gelber RD, Young ML, Dalton VK, Barr RD, Sallan SE. Induction failure in acute lymphoblastic leukemia of childhood. Cancer. 1999 Mar 15; 85(6):1395-404.
    View in: PubMed
  181. Asselin BL, Kreissman S, Coppola DJ, Bernal SD, Leavitt PR, Gelber RD, Sallan SE, Cohen HJ. Prognostic significance of early response to a single dose of asparaginase in childhood acute lymphoblastic leukemia. J Pediatr Hematol Oncol. 1999 Jan-Feb; 21(1):6-12.
    View in: PubMed
  182. Coates AS, Gelber RD, Goldhirsch A. Subsets within the chemotherapy overview. International Breast Cancer Study Group. Lancet. 1998 Nov 28; 352(9142):1783-4.
    View in: PubMed
  183. Goldhirsch A, Glick JH, Gelber RD, Senn HJ. Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer. J Natl Cancer Inst. 1998 Nov 4; 90(21):1601-8.
    View in: PubMed
  184. Pinder SE, Murray S, Ellis IO, Trihia H, Elston CW, Gelber RD, Goldhirsch A, Lindtner J, Cortés-Funes H, Simoncini E, Byrne MJ, Golouh R, Rudenstam CM, Castiglione-Gertsch M, Gusterson BA. The importance of the histologic grade of invasive breast carcinoma and response to chemotherapy. Cancer. 1998 Oct 15; 83(8):1529-39.
    View in: PubMed
  185. Colleoni M, Price K, Castiglione-Gertsch M, Goldhirsch A, Coates A, Lindtner J, Collins J, Gelber RD, Thürlimann B, Rudenstam CM. Dose-response effect of adjuvant cyclophosphamide, methotrexate, 5-fluorouracil (CMF) in node-positive breast cancer. International Breast Cancer Study Group. Eur J Cancer. 1998 Oct; 34(11):1693-700.
    View in: PubMed
  186. Goldhirsch A, Coates AS, Castiglione-Gertsch M, Gelber RD. New treatments for breast cancer: breakthroughs for patient care or just steps in the right direction? Ann Oncol. 1998 Sep; 9(9):973-6.
    View in: PubMed
  187. Bernhard J, Hürny C, Coates AS, Peterson HF, Castiglione-Gertsch M, Gelber RD, Galligioni E, Marini G, Thürlimann B, Forbes JF, Goldhirsch A, Senn HJ, Rudenstam CM. Factors affecting baseline quality of life in two international adjuvant breast cancer trials. International Breast Cancer Study Group (IBCSG). Br J Cancer. 1998 Sep; 78(5):686-93.
    View in: PubMed
  188. Neymark N, Kiebert W, Torfs K, Davies L, Fayers P, Hillner B, Gelber R, Guyatt G, Kind P, Machin D, Nord E, Osoba D, Revicki D, Schulman K, Simpson K. Methodological and statistical issues of quality of life (QoL) and economic evaluation in cancer clinical trials: report of a workshop. Eur J Cancer. 1998 Aug; 34(9):1317-33.
    View in: PubMed
  189. Kimball Dalton VM, Gelber RD, Li F, Donnelly MJ, Tarbell NJ, Sallan SE. Second malignancies in patients treated for childhood acute lymphoblastic leukemia. J Clin Oncol. 1998 Aug; 16(8):2848-53.
    View in: PubMed
  190. Cole BF, Solal-Céligny P, Gelber RD, Lepage E, Gisselbrecht C, Reyes F, Sebban C, Sugano D, Tendler C, Goldhirsch A. Quality-of-life-adjusted survival analysis of interferon alfa-2b treatment for advanced follicular lymphoma: an aid to clinical decision making. J Clin Oncol. 1998 Jul; 16(7):2339-44.
    View in: PubMed
  191. Glasziou PP, Cole BF, Gelber RD, Hilden J, Simes RJ. Quality adjusted survival analysis with repeated quality of life measures. Stat Med. 1998 Jun 15; 17(11):1215-29.
    View in: PubMed
  192. Goldhirsch A, Colleoni M, Coates AS, Castiglione-Gertsch M, Gelber RD. Adding adjuvant CMF chemotherapy to either radiotherapy or tamoxifen: are all CMFs alike? The International Breast Cancer Study Group (IBCSG). Ann Oncol. 1998 May; 9(5):489-93.
    View in: PubMed
  193. Pagani O, O'Neill A, Castiglione M, Gelber RD, Goldhirsch A, Rudenstam CM, Lindtner J, Collins J, Crivellari D, Coates A, Cavalli F, Thürlimann B, Simoncini E, Fey M, Price K, Senn HJ. Prognostic impact of amenorrhoea after adjuvant chemotherapy in premenopausal breast cancer patients with axillary node involvement: results of the International Breast Cancer Study Group (IBCSG) Trial VI. Eur J Cancer. 1998 Apr; 34(5):632-40.
    View in: PubMed
  194. Goldhirsch A, Coates AS, Colleoni M, Castiglione-Gertsch M, Gelber RD. Adjuvant chemoendocrine therapy in postmenopausal breast cancer: cyclophosphamide, methotrexate, and fluorouracil dose and schedule may make a difference. International Breast Cancer Study Group. J Clin Oncol. 1998 Apr; 16(4):1358-62.
    View in: PubMed
  195. Bernhard J, Peterson HF, Coates AS, Gusset H, Isley M, Hinkle R, Gelber RD, Castiglione-Gertsch M, Hürny C. Quality of life assessment in International Breast Cancer Study Group (IBCSG) trials: practical issues and factors associated with missing data. Stat Med. 1998 Mar 15-Apr 15; 17(5-7):587-601.
    View in: PubMed
  196. Goldhirsch A, Coates AS, Colleoni M, Gelber RD. Radiotherapy and chemotherapy in high-risk breast cancer. N Engl J Med. 1998 Jan 29; 338(5):330-1; author reply 331-2.
    View in: PubMed
  197. Goldhirsch A, Glick JH, Gelber RD, Senn HJ. International Consensus Panel on the treatment of primary breast cancer. V: Update 1998. Recent Results Cancer Res. 1998; 152:481-97.
    View in: PubMed
  198. Gelber RD, Bonetti M, Cole BF, Gelber S, Goldhirsch A. Quality of life assessment in the adjuvant setting: is it relevant? International Breast Cancer Study Group. Recent Results Cancer Res. 1998; 152:373-89.
    View in: PubMed
  199. Cole BF, Gelber RD, Kirkwood JM. Survival benefit in melanoma. J Clin Oncol. 1998 Jan; 16(1):388-9.
    View in: PubMed
  200. Silverman LB, McLean TW, Gelber RD, Donnelly MJ, Gilliland DG, Tarbell NJ, Sallan SE. Intensified therapy for infants with acute lymphoblastic leukemia: results from the Dana-Farber Cancer Institute Consortium. Cancer. 1997 Dec 15; 80(12):2285-95.
    View in: PubMed
  201. Castiglione-Gertsch M, Tattersall M, Hacking A, Goldhirsch A, Gudgeon A, Gelber RD, Lindtner J, Coates A, Collins J, Isley M, Senn HJ, Rudenstam CM. Retreating recurrent breast cancer with the same CMF-containing regimen used as adjuvant therapy. The International Breast Cancer Study Group. Eur J Cancer. 1997 Dec; 33(14):2321-5.
    View in: PubMed
  202. Bernhard J, Hürny C, Coates AS, Peterson HF, Castiglione-Gertsch M, Gelber RD, Goldhirsch A, Senn HJ, Rudenstam CM. Quality of life assessment in patients receiving adjuvant therapy for breast cancer: the IBCSG approach. The International Breast Cancer Study Group. Ann Oncol. 1997 Sep; 8(9):825-35.
    View in: PubMed
  203. Goldhirsch A, Gelber RD, Castiglione M, O'Neill A, Thürlimann B, Rudenstam CM, Lindtner J, Collins J, Forbes J, Crivellari D, Coates A, Cavalli F, Simoncini E, Fey MF, Pagani O, Price K, Senn HJ. Menstrual cycle and timing of breast surgery in premenopausal node-positive breast cancer: results of the International Breast Cancer Study Group (IBCSG) Trial VI. Ann Oncol. 1997 Aug; 8(8):751-6.
    View in: PubMed
  204. Pestalozzi BC, Peterson HF, Gelber RD, Goldhirsch A, Gusterson BA, Trihia H, Lindtner J, Cortés-Funes H, Simmoncini E, Byrne MJ, Golouh R, Rudenstam CM, Castiglione-Gertsch M, Allegra CJ, Johnston PG. Prognostic importance of thymidylate synthase expression in early breast cancer. J Clin Oncol. 1997 May; 15(5):1923-31.
    View in: PubMed
  205. Cole BF, Gelber RD, Kirkwood JM, Goldhirsch A, Barylak E, Borden E. Quality-of-life-adjusted survival analysis of interferon alfa-2b adjuvant treatment of high-risk resected cutaneous melanoma: an Eastern Cooperative Oncology Group study. J Clin Oncol. 1996 Oct; 14(10):2666-73.
    View in: PubMed
  206. Gelber RD, Goldhirsch A, Cole BF, Wieand HS, Schroeder G, Krook JE. A quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis of adjuvant radiation therapy and chemotherapy for resectable rectal cancer. J Natl Cancer Inst. 1996 Aug 7; 88(15):1039-45.
    View in: PubMed
  207. Goldhirsch A, Gelber RD. Endocrine therapies of breast cancer. Semin Oncol. 1996 Aug; 23(4):494-505.
    View in: PubMed
  208. Wallgren A, Bernier J, Gelber RD, Goldhirsch A, Roncadin M, Joseph D, Castiglione-Gertsch M. Timing of radiotherapy and chemotherapy following breast-conserving surgery for patients with node-positive breast cancer. International Breast Cancer Study Group. Int J Radiat Oncol Biol Phys. 1996 Jul 1; 35(4):649-59.
    View in: PubMed
  209. Hürny C, Bernhard J, Coates AS, Castiglione-Gertsch M, Peterson HF, Gelber RD, Forbes JF, Rudenstam CM, Simoncini E, Crivellari D, Goldhirsch A, Senn HJ. Impact of adjuvant therapy on quality of life in women with node-positive operable breast cancer. International Breast Cancer Study Group. Lancet. 1996 May 11; 347(9011):1279-84.
    View in: PubMed
  210. Brady MT, McGrath N, Brouwers P, Gelber R, Fowler MG, Yogev R, Hutton N, Bryson YJ, Mitchell CD, Fikrig S, Borkowsky W, Jimenez E, McSherry G, Rubinstein A, Wilfert CM, McIntosh K, Elkins MM, Weintrub PS. Randomized study of the tolerance and efficacy of high- versus low-dose zidovudine in human immunodeficiency virus-infected children with mild to moderate symptoms (AIDS Clinical Trials Group 128). Pediatric AIDS Clinical Trials Group. J Infect Dis. 1996 May; 173(5):1097-106.
    View in: PubMed
  211. Gelber RD, Cole BF, Goldhirsch A, Rose C, Fisher B, Osborne CK, Boccardo F, Gray R, Gordon NH, Bengtsson NO, Sevelda P. Adjuvant chemotherapy plus tamoxifen compared with tamoxifen alone for postmenopausal breast cancer: meta-analysis of quality-adjusted survival. Lancet. 1996 Apr 20; 347(9008):1066-71.
    View in: PubMed
  212. Gelber RD. Gemcitabine for pancreatic cancer: how hard to look for clinical benefit? An American perspective. Ann Oncol. 1996 Apr; 7(4):335-7.
    View in: PubMed
  213. Hürny C, Bernhard J, Coates A, Peterson HF, Castiglione-Gertsch M, Gelber RD, Rudenstam CM, Collins J, Lindtner J, Goldhirsch A, Senn HJ. Responsiveness of a single-item indicator versus a multi-item scale: assessment of emotional well-being in an international adjuvant breast cancer trial. Med Care. 1996 Mar; 34(3):234-48.
    View in: PubMed
  214. Marini G, Murray S, Goldhirsch A, Gelber RD, Castiglione-Gertsch M, Price KN, Tattersall MH, Rudenstam CM, Collins J, Lindtner J, Cavalli F, Cortés-Funes H, Gudgeon A, Forbes JF, Galligioni E, Coates AS, Senn HJ. The effect of adjuvant prednisone combined with CMF on patterns of relapse and occurrence of second malignancies in patients with breast cancer. International (Ludwig) Breast Cancer Study Group. Ann Oncol. 1996 Mar; 7(3):245-50.
    View in: PubMed
  215. Goldhirsch A, Wood WC, Senn HJ, Glick JH, Gelber RD. IX. International consensus conference on primary treatment of breast cancer. Recent Results Cancer Res. 1996; 140:325-35.
    View in: PubMed
  216. Castiglione-Gertsch M, Gelber RD, Goldhirsch A. Adjuvant systemic therapy: the issues of timing and sequence. Recent Results Cancer Res. 1996; 140:201-13.
    View in: PubMed
  217. Smith M, Arthur D, Camitta B, Carroll AJ, Crist W, Gaynon P, Gelber R, Heerema N, Korn EL, Link M, Murphy S, Pui CH, Pullen J, Reamon G, Sallan SE, Sather H, Shuster J, Simon R, Trigg M, Tubergen D, Uckun F, Ungerleider R. Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia. J Clin Oncol. 1996 Jan; 14(1):18-24.
    View in: PubMed
  218. Lallemant M, Le Coeur S, McIntosh K, Brennan T, Gelber R, Lee TH, Hammer S, Essex M, Vithayasai V, Sirivatanapa P, et al. AZT trial in Thailand. Science. 1995 Nov 10; 270(5238):899-900.
    View in: PubMed
  219. Goldhirsch A, Wood WC, Senn HJ, Glick JH, Gelber RD. Meeting highlights: international consensus panel on the treatment of primary breast cancer. J Natl Cancer Inst. 1995 Oct 4; 87(19):1441-5.
    View in: PubMed
  220. Crivellari D, Price KN, Hagen M, Goldhirsch A, Gelber RD, Castiglione M, Coates AS, Rudenstam CM, Collins J, Lindtner J, et al. Routine tests during follow-up of patients after primary treatment for operable breast cancer. International (Ludwig) Breast Cancer Study Group (IBCSG) Ann Oncol. 1995 Oct; 6(8):769-76.
    View in: PubMed
  221. Goldhirsch A, Wood WC, Senn HJ, Glick JH, Gelber RD. Fifth International Conference on Adjuvant Therapy of Breast Cancer, St Gallen, March 1995. International Consensus Panel on the Treatment of Primary Breast Cancer. Eur J Cancer. 1995 Oct; 31A(11):1754-9.
    View in: PubMed
  222. Cole BF, Gelber RD, Goldhirsch A. A quality-adjusted survival meta-analysis of adjuvant chemotherapy for premenopausal breast cancer. International Breast Cancer Study Group. Stat Med. 1995 Aug 30; 14(16):1771-84.
    View in: PubMed
  223. Schwartz CE, Cole BF, Gelber RD. Measuring patient-centered outcomes in neurologic disease. Extending the Q-TWiST method. Arch Neurol. 1995 Aug; 52(8):754-62.
    View in: PubMed
  224. Gelber RD, Cole BF, Goldhirsch A, Bonadonna G, Howell A, McArdle CS, Mouridsen HT, Rubens RD, Welvaart K. Adjuvant chemotherapy for premenopausal breast cancer: a meta-analysis using quality-adjusted survival. Cancer J Sci Am. 1995 Jul-Aug; 1(2):114-21.
    View in: PubMed
  225. Lipshultz SE, Lipsitz SR, Mone SM, Goorin AM, Sallan SE, Sanders SP, Orav EJ, Gelber RD, Colan SD. Female sex and drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer. N Engl J Med. 1995 Jun 29; 332(26):1738-43.
    View in: PubMed
  226. Schwartz CE, Cole BF, Vickrey BG, Gelber RD. The Q-TWiST approach to assessing health-related quality of life in epilepsy. Qual Life Res. 1995 Apr; 4(2):135-41.
    View in: PubMed
  227. Hürny C, Bernhard J, Coates A, Peterson HF, Gelber RD. The quality of quality-of-life measurements. JAMA. 1995 Mar 15; 273(11):843; author reply 844-5.
    View in: PubMed
  228. Goldhirsch A, Gelber RD, Castiglione M, Price KN, Rudenstam CM, Lindtner J, Collins J, Senn HJ, Cavalli F, Galligioni E, et al. The best available adjuvant treatments are within the framework of clinical trials. The International Breast Cancer Study Group. Isr J Med Sci. 1995 Feb-Mar; 31(2-3):144-54.
    View in: PubMed
  229. Gelber RD, Gelber S. Quality-of-life assessment in clinical trials. Cancer Treat Res. 1995; 75:225-46.
    View in: PubMed
  230. Spector SA, Gelber RD, McGrath N, Wara D, Barzilai A, Abrams E, Bryson YJ, Dankner WM, Livingston RA, Connor EM. A controlled trial of intravenous immune globulin for the prevention of serious bacterial infections in children receiving zidovudine for advanced human immunodeficiency virus infection. Pediatric AIDS Clinical Trials Group. N Engl J Med. 1994 Nov 3; 331(18):1181-7.
    View in: PubMed
  231. Connor EM, Sperling RS, Gelber R, Kiselev P, Scott G, O'Sullivan MJ, VanDyke R, Bey M, Shearer W, Jacobson RL, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med. 1994 Nov 3; 331(18):1173-80.
    View in: PubMed
  232. Castiglione-Gertsch M, Johnsen C, Goldhirsch A, Gelber RD, Rudenstam CM, Collins J, Lindtner J, Hacking A, Cortes-Funes H, Forbes J, et al. The International (Ludwig) Breast Cancer Study Group Trials I-IV: 15 years follow-up. Ann Oncol. 1994 Oct; 5(8):717-24.
    View in: PubMed
  233. Cole BF, Gelber RD, Anderson KM. Parametric approaches to quality-adjusted survival analysis. International Breast Cancer Study Group. Biometrics. 1994 Sep; 50(3):621-31.
    View in: PubMed
  234. Goldhirsch A, Gelber RD, Castiglione M, Price KN, Rudenstam CM, Lindtner J, Collins J, Senn HJ, Brunner KW, Galligioni E, et al. Present and future projects of the International Breast Cancer Study Group. Cancer. 1994 Aug 1; 74(3 Suppl):1139-49.
    View in: PubMed
  235. Goldhirsch A, Gelber RD. Understanding adjuvant chemotherapy for breast cancer. N Engl J Med. 1994 May 5; 330(18):1308-9.
    View in: PubMed
  236. Gelber RD, Goldhirsch A. Radiotherapy to the conserved breast: is it avoidable if the cancer is small? J Natl Cancer Inst. 1994 May 4; 86(9):652-4.
    View in: PubMed
  237. Nathan B, Gusterson B, Jadayel D, O'Hare M, Anbazhagan R, Jayatilake H, Ebbs S, Micklem K, Price K, Gelber R, et al. Expression of BCL-2 in primary breast cancer and its correlation with tumour phenotype. For the International (Ludwig) Breast Cancer Study Group. Ann Oncol. 1994 May; 5(5):409-14.
    View in: PubMed
  238. Goldhirsch A, Gelber RD, Castiglione M. Testing tumor dormancy in breast cancer. J Natl Cancer Inst. 1994 Apr 6; 86(7):558.
    View in: PubMed
  239. Schorin MA, Blattner S, Gelber RD, Tarbell NJ, Donnelly M, Dalton V, Cohen HJ, Sallan SE. Treatment of childhood acute lymphoblastic leukemia: results of Dana-Farber Cancer Institute/Children's Hospital Acute Lymphoblastic Leukemia Consortium Protocol 85-01. J Clin Oncol. 1994 Apr; 12(4):740-7.
    View in: PubMed
  240. Lenderking WR, Gelber RD, Cotton DJ, Cole BF, Goldhirsch A, Volberding PA, Testa MA. Evaluation of the quality of life associated with zidovudine treatment in asymptomatic human immunodeficiency virus infection. The AIDS Clinical Trials Group. N Engl J Med. 1994 Mar 17; 330(11):738-43.
    View in: PubMed
  241. Goldhirsch A, Gelber RD, Price KN, Castiglione M, Coates AS, Rudenstam CM, Collins J, Lindtner J, Hacking A, Marini G, et al. Effect of systemic adjuvant treatment on first sites of breast cancer relapse. Lancet. 1994 Feb 12; 343(8894):377-81.
    View in: PubMed
  242. Hürny C, Bernhard J, Coates A, Castiglione M, Peterson HF, Gelber RD, Rudenstam CM, Goldhirsch A, Senn HJ. Timing of baseline quality of life assessment in an international adjuvant breast cancer trial: its effect on patient self-estimation. The International Breast Cancer Study Group. Ann Oncol. 1994 Jan; 5(1):65-74.
    View in: PubMed
  243. Gelber RD, Goldhirsch A, Cole BF. Parametric extrapolation of survival estimates with applications to quality of life evaluation of treatments. International Breast Cancer Study Group. Control Clin Trials. 1993 Dec; 14(6):485-99.
    View in: PubMed
  244. Gelber RD, Goldhirsch A, Castiglione M, Rudenstram CM, Collins J, Senn HJ. Premenopausal oopherectomy versus CMF chemotherapy in stage II breast carcinoma. The International Breast Cancer Study Group (IBCSG) Lancet. 1993 Jul 31; 342(8866):305.
    View in: PubMed
  245. Gelber RD, Sallan SE, Cohen HJ, Donnelly M, Dalton V, Tobia F, Clavell LA, Tarbell NJ. Central nervous system treatment in childhood acute lymphoblastic leukemia. Long-term follow-up of patients diagnosed between 1973 and 1985. Cancer. 1993 Jul 1; 72(1):261-70.
    View in: PubMed
  246. Tarbell NJ, Gelber RD, Weinstein HJ, Mauch P. Sex differences in risk of second malignant tumours after Hodgkin's disease in childhood. Lancet. 1993 Jun 5; 341(8858):1428-32.
    View in: PubMed
  247. Cole BF, Gelber RD, Goldhirsch A. Cox regression models for quality adjusted survival analysis. Stat Med. 1993 May 30; 12(10):975-87.
    View in: PubMed
  248. Filocoma D, Needleman HL, Arceci R, Gelber RD, Donnelly M. Pediatric histiocytosis. Characterization, prognosis, and oral involvement. Am J Pediatr Hematol Oncol. 1993 May; 15(2):226-30.
    View in: PubMed
  249. Zerbini C, Gelber RD, Weinberg D, Sallan SE, Barnes P, Kupsky W, Scott RM, Tarbell NJ. Prognostic factors in medulloblastoma, including DNA ploidy. J Clin Oncol. 1993 Apr; 11(4):616-22.
    View in: PubMed
  250. Billett AL, Kornmehl E, Tarbell NJ, Weinstein HJ, Gelber RD, Ritz J, Sallan SE. Autologous bone marrow transplantation after a long first remission for children with recurrent acute lymphoblastic leukemia. Blood. 1993 Mar 15; 81(6):1651-7.
    View in: PubMed
  251. Gelber RD, Goldhirsch A, Coates AS. Adjuvant therapy for breast cancer: understanding the overview. International Breast Cancer Study Group. J Clin Oncol. 1993 Mar; 11(3):580-5.
    View in: PubMed
  252. Gelber RD, Goldhirsch A, Cole BF. Evaluation of effectiveness: Q-TWiST. The International Breast Cancer Study Group. Cancer Treat Rev. 1993; 19 Suppl A:73-84.
    View in: PubMed
  253. Gelber RD, Cole BF, Goldhirsch A. How to compare quality of life of breast cancer patients in clinical trials. International Breast Cancer Study Group. Recent Results Cancer Res. 1993; 127:221-33.
    View in: PubMed
  254. Gelber RD, Goldhirsch A. From the overview to the patient: how to interpret meta-analysis data. Recent Results Cancer Res. 1993; 127:167-76.
    View in: PubMed
  255. Glick JH, Gelber RD, Goldhirsch A, Senn HJ. Adjuvant therapy of primary breast cancer: closing summary. Recent Results Cancer Res. 1993; 127:289-300.
    View in: PubMed
  256. Glick JH, Gelber RD, Goldhirsch A, Senn HJ. Adjuvant therapy of primary breast cancer. 4th International Conference on Adjuvant Therapy of Primary Breast Cancer St. Gallen, Switzerland. Ann Oncol. 1992 Dec; 3(10):801-7.
    View in: PubMed
  257. Spataro V, Price K, Goldhirsch A, Cavalli F, Simoncini E, Castiglione M, Rudenstam CM, Collins J, Lindtner J, Gelber RD. Sequential estrogen receptor determinations from primary breast cancer and at relapse: prognostic and therapeutic relevance. The International Breast Cancer Study Group (formerly Ludwig Group). Ann Oncol. 1992 Nov; 3(9):733-40.
    View in: PubMed
  258. Gelber RD, Coates AS, Goldhirsch A. Meta-analysis: the fashion of summing-up evidence. Part II: Interpretations and uses. Ann Oncol. 1992 Nov; 3(9):683-91.
    View in: PubMed
  259. Kreissman SG, Gelber RD, Cohen HJ, Clavell LA, Leavitt P, Sallan SE. Incidence of secondary acute myelogenous leukemia after treatment of childhood acute lymphoblastic leukemia. Cancer. 1992 Oct 15; 70(8):2208-13.
    View in: PubMed
  260. Glick JH, Gelber RD, Goldhirsch A, Senn HJ. Meeting highlights: adjuvant therapy for primary breast cancer. J Natl Cancer Inst. 1992 Oct 7; 84(19):1479-85.
    View in: PubMed
  261. Gusterson BA, Gelber RD, Goldhirsch A, Price KN, Säve-Söderborgh J, Anbazhagan R, Styles J, Rudenstam CM, Golouh R, Reed R, et al. Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group. J Clin Oncol. 1992 Jul; 10(7):1049-56.
    View in: PubMed
  262. Billett AL, Carls A, Gelber RD, Sallan SE. Allergic reactions to Erwinia asparaginase in children with acute lymphoblastic leukemia who had previous allergic reactions to Escherichia coli asparaginase. Cancer. 1992 Jul 1; 70(1):201-6.
    View in: PubMed
  263. Gelber RD, Lenderking WR, Cotton DJ, Cole BF, Fischl MA, Goldhirsch A, Testa MA. Quality-of-life evaluation in a clinical trial of zidovudine therapy in patients with mildly symptomatic HIV infection. The AIDS Clinical Trials Group. Ann Intern Med. 1992 Jun 15; 116(12 Pt 1):961-6.
    View in: PubMed
  264. Waber DP, Tarbell NJ, Kahn CM, Gelber RD, Sallan SE. The relationship of sex and treatment modality to neuropsychologic outcome in childhood acute lymphoblastic leukemia. J Clin Oncol. 1992 May; 10(5):810-7.
    View in: PubMed
  265. Neville AM, Bettelheim R, Gelber RD, Säve-Söderbergh J, Davis BW, Reed R, Torhorst J, Golouh R, Peterson HF, Price KN, et al. Factors predicting treatment responsiveness and prognosis in node-negative breast cancer. The International (Ludwig) Breast Cancer Study Group. J Clin Oncol. 1992 May; 10(5):696-705.
    View in: PubMed
  266. Gelber RD, Coates AS, Goldhirsch A. Adjuvant treatment for breast cancer: the overview. BMJ. 1992 Apr 4; 304(6831):859-60.
    View in: PubMed
  267. Drigan R, Spirito A, Gelber RD. Behavioral effects of corticosteroids in children with acute lymphoblastic leukemia. Med Pediatr Oncol. 1992; 20(1):13-21.
    View in: PubMed
  268. Gelber RD, Goldhirsch A, Hürny C, Bernhard J, Simes RJ. Quality of life in clinical trials of adjuvant therapies. International Breast Cancer Study Group (formerly Ludwig Group). J Natl Cancer Inst Monogr. 1992; (11):127-35.
    View in: PubMed
  269. Grier HE, Gelber RD, Link MP, Camitta BP, Clavell LA, Weistein HJ. Intensive sequential chemotherapy for children with acute myelogenous leukemia: VAPA, 80-035, and HI-C-Daze. Leukemia. 1992; 6 Suppl 2:48-51.
    View in: PubMed
  270. Hürny C, Bernhard J, Gelber RD, Coates A, Castiglione M, Isley M, Dreher D, Peterson H, Goldhirsch A, Senn HJ. Quality of life measures for patients receiving adjuvant therapy for breast cancer: an international trial. The International Breast Cancer Study Group. Eur J Cancer. 1992; 28(1):118-24.
    View in: PubMed
  271. Gelber RD, Goldhirsch A. Reporting and interpreting adjuvant therapy clinical trials. International Breast Cancer Study Group (formerly Ludwig Group). J Natl Cancer Inst Monogr. 1992; (11):59-69.
    View in: PubMed
  272. Gelber RD, Goldhirsch A. Models for weighing benefits and toxicities. Cancer Treat Res. 1992; 60:189-206.
    View in: PubMed
  273. Goldhirsch A, Castiglione M, Gelber RD. A single perioperative adjuvant chemotherapy course for node-negative breast cancer: five-year results of trial V. International Breast Cancer Study Group (formerly Ludwig Group). J Natl Cancer Inst Monogr. 1992; (11):89-96.
    View in: PubMed
  274. Niemeyer CM, Gelber RD, Tarbell NJ, Donnelly M, Clavell LA, Blattner SR, Donahue K, Cohen HJ, Sallan SE. Low-dose versus high-dose methotrexate during remission induction in childhood acute lymphoblastic leukemia (Protocol 81-01 update). Blood. 1991 Nov 15; 78(10):2514-9.
    View in: PubMed
  275. Niemeyer CM, Reiter A, Riehm H, Donnelly M, Gelber RD, Sallan SE. Comparative results of two intensive treatment programs for childhood acute lymphoblastic leukemia: The Berlin-Frankfurt-Münster and Dana-Farber Cancer Institute protocols. Ann Oncol. 1991 Nov-Dec; 2(10):745-9.
    View in: PubMed
  276. Taylor CW, Anbazhagan R, Jayatilake H, Adams A, Gusterson BA, Price K, Gelber RD, Goldhirsch A. Helix pomatia in breast cancer. Lancet. 1991 Aug 31; 338(8766):580-1.
    View in: PubMed
  277. Gelber RD, Goldhirsch A. Meta-analysis: the fashion of summing-up evidence. Part I. Rationale and conduct. Ann Oncol. 1991 Jul; 2(7):461-8.
    View in: PubMed
  278. Neville AM, Price KN, Gelber RD, Goldhirsch A. Axillary node micrometastases and breast cancer. Lancet. 1991 May 4; 337(8749):1110.
    View in: PubMed
  279. Gelber RD, Goldhirsch A, Cavalli F. Quality-of-life-adjusted evaluation of adjuvant therapies for operable breast cancer. The International Breast Cancer Study Group. Ann Intern Med. 1991 Apr 15; 114(8):621-8.
    View in: PubMed
  280. Lipshultz SE, Colan SD, Gelber RD, Perez-Atayde AR, Sallan SE, Sanders SP. Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N Engl J Med. 1991 Mar 21; 324(12):808-15.
    View in: PubMed
  281. Goldhirsch A, Gelber RD, Castiglione M. Adjuvant therapy of breast cancer. International Breast Cancer Study Group. Eur J Cancer. 1991; 27(3):389-99.
    View in: PubMed
  282. Anbazhagan R, Gelber RD, Bettelheim R, Goldhirsch A, Gusterson BA. Association of c-erbB-2 expression and S-phase fraction in the prognosis of node positive breast cancer. Ann Oncol. 1991 Jan; 2(1):47-53.
    View in: PubMed
  283. Sonis AL, Tarbell N, Valachovic RW, Gelber R, Schwenn M, Sallan S. Dentofacial development in long-term survivors of acute lymphoblastic leukemia. A comparison of three treatment modalities. Cancer. 1990 Dec 15; 66(12):2645-52.
    View in: PubMed
  284. Byar DP, Schoenfeld DA, Green SB, Amato DA, Davis R, De Gruttola V, Finkelstein DM, Gatsonis C, Gelber RD, Lagakos S, et al. Design considerations for AIDS trials. N Engl J Med. 1990 Nov 8; 323(19):1343-8.
    View in: PubMed
  285. Glasziou PP, Simes RJ, Gelber RD. Quality adjusted survival analysis. Stat Med. 1990 Nov; 9(11):1259-76.
    View in: PubMed
  286. Longmore G, Guinan EC, Weinstein HJ, Gelber RD, Rappeport JM, Antin JH. Bone marrow transplantation for myelodysplasia and secondary acute nonlymphoblastic leukemia. J Clin Oncol. 1990 Oct; 8(10):1707-14.
    View in: PubMed
  287. Neville AM, Bettelheim R, Gelber RD, Goldhirsch A. Occult axillary lymph-node micrometastases in breast cancer. Lancet. 1990 Sep 22; 336(8717):759.
    View in: PubMed
  288. Goldhirsch A, Gelman RS, Gelber RD, Castiglione M. Treatment of breast cancer in elderly patients. Lancet. 1990 Sep 1; 336(8714):564.
    View in: PubMed
  289. Richner J, Gerber HA, Locher GW, Goldhirsch A, Gelber RD, Gullick WJ, Berger MS, Groner B, Hynes NE. c-erbB-2 protein expression in node negative breast cancer. Ann Oncol. 1990 Jul; 1(4):263-8.
    View in: PubMed
  290. Goldhirsch A, Castiglione M, Gelber RD. Adjuvant chemo-endocrine therapy in postmenopausal women with breast cancer and axillary-node metastases. Lancet. 1990 May 5; 335(8697):1099-100.
    View in: PubMed
  291. Gelman R, Gelber R, Henderson IC, Coleman CN, Harris JR. Improved methodology for analyzing local and distant recurrence. J Clin Oncol. 1990 Mar; 8(3):548-55.
    View in: PubMed
  292. Waber DP, Urion DK, Tarbell NJ, Niemeyer C, Gelber R, Sallan SE. Late effects of central nervous system treatment of acute lymphoblastic leukemia in childhood are sex-dependent. Dev Med Child Neurol. 1990 Mar; 32(3):238-48.
    View in: PubMed
  293. Castiglione M, Gelber RD, Goldhirsch A. Adjuvant systemic therapy for breast cancer in the elderly: competing causes of mortality. International Breast Cancer Study Group. J Clin Oncol. 1990 Mar; 8(3):519-26.
    View in: PubMed
  294. Goldhirsch A, Gelber RD, Castiglione M. The magnitude of endocrine effects of adjuvant chemotherapy for premenopausal breast cancer patients. The International Breast Cancer Study Group. Ann Oncol. 1990; 1(3):183-8.
    View in: PubMed
  295. Sallan SE, Gelber RD, Kimball V, Donnelly M, Cohen HJ. More is better! Update of Dana-Farber Cancer Institute/Children's Hospital childhood acute lymphoblastic leukemia trials. Haematol Blood Transfus. 1990; 33:459-66.
    View in: PubMed
  296. Grier HE, Gelber RD, Clavell LA, Camitta BM, Link MP, Garcea MJ, Weinstein HJ. Intensive sequential chemotherapy for children with acute myelogenous leukemia. Haematol Blood Transfus. 1990; 33:193-7.
    View in: PubMed
  297. Sallan SE, Niemeyer CM, Billett AL, Lipton JM, Tarbell NJ, Gelber RD, Murray C, Pittinger TP, Wolfe LC, Bast RC, et al. Autologous bone marrow transplantation for acute lymphoblastic leukemia. J Clin Oncol. 1989 Nov; 7(11):1594-601.
    View in: PubMed
  298. Fletcher JA, Kimball VM, Lynch E, Donnelly M, Pavelka K, Gelber RD, Tantravahi R, Sallan SE. Prognostic implications of cytogenetic studies in an intensively treated group of children with acute lymphoblastic leukemia. Blood. 1989 Nov 1; 74(6):2130-5.
    View in: PubMed
  299. Gelber RD, Gelman RS, Goldhirsch A. A quality-of-life-oriented endpoint for comparing therapies. Biometrics. 1989 Sep; 45(3):781-95.
    View in: PubMed
  300. Gelber RD, Goldhirsch A. Clinical trials for clinicians. Chest. 1989 Jul; 96(1 Suppl):97S-101S.
    View in: PubMed
  301. Gelber RD, Goldhirsch A, Castiglione M. The duration of a life of quality should become the focus of "quality-of-life" studies. J Clin Oncol. 1989 Apr; 7(4):542-4.
    View in: PubMed
  302. Goldhirsch A, Gelber RD. Randomized perioperative therapy in operable breast cancer: the Ludwig Trial V. Recent Results Cancer Res. 1989; 115:43-53.
    View in: PubMed
  303. Goldhirsch A, Gelber RD, Simes RJ, Glasziou P, Coates AS. Costs and benefits of adjuvant therapy in breast cancer: a quality-adjusted survival analysis. J Clin Oncol. 1989 Jan; 7(1):36-44.
    View in: PubMed
  304. Goldhirsch A, Gelber RD. Adjuvant chemo-endocrine therapy or endocrine therapy alone for postmenopausal patients: Ludwig Studies III and IV. Recent Results Cancer Res. 1989; 115:153-62.
    View in: PubMed
  305. Gelber RD, Goldhirsch A. Comparison of adjuvant therapies using quality-of-life considerations. Int J Technol Assess Health Care. 1989; 5(3):401-13.
    View in: PubMed
  306. Gelber RD, Goldhirsch A. Methods for assessing treatment efficacy in trials for adjuvant therapy for breast cancer. Recent Results Cancer Res. 1989; 115:211-9.
    View in: PubMed
  307. Gelber RD. Critical review: methodology of adjuvant trials and interpretation of results. Recent Results Cancer Res. 1989; 115:236-8.
    View in: PubMed
  308. Healy GB, Gelber RD, Trowbridge AL, Grundfast KM, Ruben RJ, Price KN. Treatment of recurrent respiratory papillomatosis with human leukocyte interferon. Results of a multicenter randomized clinical trial. N Engl J Med. 1988 Aug 18; 319(7):401-7.
    View in: PubMed
  309. Gelber RD, Goldhirsch A. Can a clinical trial be the treatment of choice for patients with cancer? J Natl Cancer Inst. 1988 Aug 17; 80(12):886-7.
    View in: PubMed
  310. Hoover DL, Smith LE, Turner SJ, Gelber RD, Sallan SE. Ophthalmic evaluation of survivors of acute lymphoblastic leukemia. Ophthalmology. 1988 Feb; 95(2):151-5.
    View in: PubMed
  311. Goldhirsch A, Gelber RD, Castiglione M. Relapse of breast cancer after adjuvant treatment in premenopausal and perimenopausal women: patterns and prognoses. J Clin Oncol. 1988 Jan; 6(1):89-97.
    View in: PubMed
  312. Gelber RD, Goldhirsch A. Meta-analysis in clinical research. Ann Intern Med. 1988 Jan; 108(1):158-9.
    View in: PubMed
  313. Hedley DW, Rugg CA, Gelber RD. Association of DNA index and S-phase fraction with prognosis of nodes positive early breast cancer. Cancer Res. 1987 Sep 1; 47(17):4729-35.
    View in: PubMed
  314. Kramer S, Gelber RD, Snow JB, Marcial VA, Lowry LD, Davis LW, Chandler R. Combined radiation therapy and surgery in the management of advanced head and neck cancer: final report of study 73-03 of the Radiation Therapy Oncology Group. Head Neck Surg. 1987 Sep-Oct; 10(1):19-30.
    View in: PubMed
  315. Goldhirsch A, Gelber RD, Tattersall MN, Rudenstam CM, Cavalli F. Methotrexate/nitrous-oxide toxic interaction in perioperative chemotherapy for early breast cancer. Lancet. 1987 Jul 18; 2(8551):151.
    View in: PubMed
  316. Grier HE, Gelber RD, Camitta BM, Delorey MJ, Link MP, Price KN, Leavitt PR, Weinstein HJ. Prognostic factors in childhood acute myelogenous leukemia. J Clin Oncol. 1987 Jul; 5(7):1026-32.
    View in: PubMed
  317. Gelber RD, Goldhirsch A. Interpretation of results from subset analyses within overviews of randomized clinical trials. Stat Med. 1987 Apr-May; 6(3):371-88.
    View in: PubMed
  318. Li FP, Gimbrere K, Gelber RD, Sallan SE, Flamant F, Green DM, Heyn RM, Meadows AT. Outcome of pregnancy in survivors of Wilms' tumor. JAMA. 1987 Jan 9; 257(2):216-9.
    View in: PubMed
  319. Weinstein H, Grier H, Gelber R, Camitta B, Link M, Delorey M, Price K. Postremission induction intensive sequential chemotherapy for children with AML--treatment results and prognostic factors. Haematol Blood Transfus. 1987; 30:88-92.
    View in: PubMed
  320. Davis BW, Gelber RD, Goldhirsch A, Hartmann WH, Locher GW, Reed R, Golouh R, Säve-Söderbergh J, Holloway L, Russell I, et al. Prognostic significance of tumor grade in clinical trials of adjuvant therapy for breast cancer with axillary lymph node metastasis. Cancer. 1986 Dec 15; 58(12):2662-70.
    View in: PubMed
  321. Gelber RD, Goldhirsch A. A new endpoint for the assessment of adjuvant therapy in postmenopausal women with operable breast cancer. J Clin Oncol. 1986 Dec; 4(12):1772-9.
    View in: PubMed
  322. Gelber RD, Goldhirsch A. The concept of an overview of cancer clinical trials with special emphasis on early breast cancer. J Clin Oncol. 1986 Nov; 4(11):1696-703.
    View in: PubMed
  323. Clavell LA, Gelber RD, Cohen HJ, Hitchcock-Bryan S, Cassady JR, Tarbell NJ, Blattner SR, Tantravahi R, Leavitt P, Sallan SE. Four-agent induction and intensive asparaginase therapy for treatment of childhood acute lymphoblastic leukemia. N Engl J Med. 1986 Sep 11; 315(11):657-63.
    View in: PubMed
  324. Himel HN, Liberati A, Gelber RD, Chalmers TC. Adjuvant chemotherapy for breast cancer. A pooled estimate based on published randomized control trials. JAMA. 1986 Sep 5; 256(9):1148-59.
    View in: PubMed
  325. Rohatiner A, Gelber R, Schlossman SF, Ritz J. Depletion of T cells from human bone marrow using monoclonal antibodies and rabbit complement. A quantitative and functional analysis. Transplantation. 1986 Jul; 42(1):73-80.
    View in: PubMed
  326. Pedrazzini A, Gelber R, Isley M, Castiglione M, Goldhirsch A. First repeated bone scan in the observation of patients with operable breast cancer. J Clin Oncol. 1986 Mar; 4(3):389-94.
    View in: PubMed
  327. Hitchcock-Bryan S, Gelber R, Cassady JR, Sallan SE. The impact of induction anthracycline on long-term failure-free survival in childhood acute lymphoblastic leukemia. Med Pediatr Oncol. 1986; 14(4):211-5.
    View in: PubMed
  328. Goldhirsch A, Gelber R. Perioperative and conventionally timed chemotherapy in operable breast cancer: the Ludwig Breast Cancer Study V. Recent Results Cancer Res. 1986; 103:103-12.
    View in: PubMed
  329. Goldhirsch A, Gelber R. Adjuvant treatment for early breast cancer: the Ludwig breast cancer studies. NCI Monogr. 1986; (1):55-70.
    View in: PubMed
  330. Davis BW, Gelber R, Goldhirsch A, Hartmann WH, Hollaway L, Russell I, Rudenstam CM. Prognostic significance of peritumoral vessel invasion in clinical trials of adjuvant therapy for breast cancer with axillary lymph node metastasis. Hum Pathol. 1985 Dec; 16(12):1212-8.
    View in: PubMed
  331. Anderson JR, Cain KC, Gelber RD, Gelman RS. Analysis and interpretation of the comparison of survival by treatment outcome variables in cancer clinical trials. Cancer Treat Rep. 1985 Oct; 69(10):1139-46.
    View in: PubMed
  332. Goldhirsch A, Gelber RD, Cavalli F, Rudenstam CM, Tattersall MN. Adjuvant therapy in postmenopausal node-positive breast cancer. J Clin Oncol. 1985 Jul; 3(7):1045-7.
    View in: PubMed
  333. Goldhirsch A, Gelber RD, Tattersall MN, Rudenstam CM, Cavalli F. Endocrine adjuvant therapy for breast cancer. Lancet. 1985 Jun 1; 1(8440):1274.
    View in: PubMed
  334. Goorin AM, Hershey BJ, Levin MJ, Siber GR, Gelber RD, Flynn K, Lew M, Beckett K, Blanding P, Sallan SE. Use of trimethoprim-sulfamethoxazole to prevent bacterial infections in children with acute lymphoblastic leukemia. Pediatr Infect Dis. 1985 May-Jun; 4(3):265-9.
    View in: PubMed
  335. Rominger CJ, Gunderson LL, Gelber RD, Conner N. Radiation therapy alone or in combination with chemotherapy in the treatment of residual or inoperable carcinoma of the rectum and rectosigmoid or pelvic recurrence following colorectal surgery. Radiation Therapy Oncology Group study (76-16). Am J Clin Oncol. 1985 Apr; 8(2):118-27.
    View in: PubMed
  336. Danjoux CE, Gelber RD, Catton GE, Klaassen DJ. Combination chemo-radiotherapy for residual, recurrent or inoperable carcinoma of the rectum: E.C.O.G. study (EST 3276). Int J Radiat Oncol Biol Phys. 1985 Apr; 11(4):765-71.
    View in: PubMed
  337. Bast RC, De Fabritiis P, Lipton J, Gelber R, Maver C, Nadler L, Sallan S, Ritz J. Elimination of malignant clonogenic cells from human bone marrow using multiple monoclonal antibodies and complement. Cancer Res. 1985 Feb; 45(2):499-503.
    View in: PubMed
  338. Gelber RD. Methodological and statistical aspects in perioperative chemotherapy trials. Recent Results Cancer Res. 1985; 98:53-63.
    View in: PubMed
  339. Goorin AM, Delorey MJ, Lack EE, Gelber RD, Price K, Cassady JR, Levey R, Tapper D, Jaffe N, Link M, et al. Prognostic significance of complete surgical resection of pulmonary metastases in patients with osteogenic sarcoma: analysis of 32 patients. J Clin Oncol. 1984 May; 2(5):425-31.
    View in: PubMed
  340. Gelber RD. Ludwig Breast Cancer trial LBCS III: chemo- and endocrine adjuvant treatment in postmenopausal patients. Recent Results Cancer Res. 1984; 96:102-9.
    View in: PubMed
  341. Li FP, Yan JC, Sallan S, Cassady JR, Danahy J, Fine W, Gelber RD, Green DM. Second neoplasms after Wilms' tumor in childhood. J Natl Cancer Inst. 1983 Dec; 71(6):1205-9.
    View in: PubMed
  342. Anderson JR, Cain KC, Gelber RD. Analysis of survival by tumor response. J Clin Oncol. 1983 Nov; 1(11):710-9.
    View in: PubMed
  343. Sallan SE, Hitchcock-Bryan S, Gelber R, Cassady JR, Frei E, Nathan DG. Influence of intensive asparaginase in the treatment of childhood non-T-cell acute lymphoblastic leukemia. Cancer Res. 1983 Nov; 43(11):5601-7.
    View in: PubMed
  344. Weinstein HJ, Mayer RJ, Rosenthal DS, Coral FS, Camitta BM, Gelber RD. Chemotherapy for acute myelogenous leukemia in children and adults: VAPA update. Blood. 1983 Aug; 62(2):315-9.
    View in: PubMed
  345. Reddy S, Hendrickson FR, Hoeksema J, Gelber R. The role of radiation therapy in the palliation of metastatic genitourinary tract carcinomas. A study of the Radiation Therapy Oncology Group. Cancer. 1983 Jul 1; 52(1):25-9.
    View in: PubMed
  346. Kaplan MM, Garnick MB, Gelber R, Li FP, Cassady JR, Sallan SE, Fine WE, Sack MJ. Risk factors for thyroid abnormalities after neck irradiation for childhood cancer. Am J Med. 1983 Feb; 74(2):272-80.
    View in: PubMed
  347. Weinstein HJ, Mayer RJ, Rosenthal DS, Coral FS, Camitta BM, Gelber RD, Nathan DG, Frei E. The treatment of acute myelogenous leukemia in children and adults: VAPA update. Haematol Blood Transfus. 1983; 28:41-5.
    View in: PubMed
  348. Taylor SG, Gelber RD. Experience of the Eastern Cooperative Oncology Group with doxorubicin as a single agent in patients with previously untreated breast cancer. Cancer Treat Rep. 1982 Jul; 66(7):1594-5.
    View in: PubMed
  349. Marcial VA, Gelber R, Kramer S, Snow JB, Davis LW, Vallecillo LA. Does preoperative irradiation increase the rate of surgical complications in carcinoma of the head and neck? A Radiation Therapy Oncology Group Report. Cancer. 1982 Mar 15; 49(6):1297-301.
    View in: PubMed
  350. Borgelt B, Gelber R, Larson M, Hendrickson F, Griffin T, Roth R. Ultra-rapid high dose irradiation schedules for the palliation of brain metastases: final results of the first two studies by the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys. 1981 Dec; 7(12):1633-8.
    View in: PubMed
  351. Gelber RD, Larson M, Borgelt BB, Kramer S. Equivalence of radiation schedules for the palliative treatment of brain metastases in patients with favorable prognosis. Cancer. 1981 Oct 15; 48(8):1749-53.
    View in: PubMed
  352. Cronin CM, Sallan SE, Gelber R, Lucas VS, Laszlo J. Antiemetic effect of intramuscular levonantradol in patients receiving anticancer chemotherapy. J Clin Pharmacol. 1981 Aug-Sep; 21(8-9 Suppl):43S-50S.
    View in: PubMed
  353. Kurtz JM, Gelber R, Brady LW, Carella RJ, Cooper JS. The palliation of brain metastases in a favorable patient population: a randomized clinical trial by the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys. 1981 Jul; 7(7):891-5.
    View in: PubMed
  354. Borgelt BB, Gelber R, Brady LW, Griffin T, Hendrickson FR. The palliation of hepatic metastases: results of the Radiation Therapy Oncology Group pilot study. Int J Radiat Oncol Biol Phys. 1981 May; 7(5):587-91.
    View in: PubMed
  355. Horton J, Gelber RD, Engstrom P, Falkson G, Moertel C, Brodovsky H, Douglass H. Trials of single-agent and combination chemotherapy for advanced cancer of the pancreas. Cancer Treat Rep. 1981 Jan-Feb; 65(1-2):65-8.
    View in: PubMed
  356. Stillman RJ, Schinfeld JS, Schiff I, Gelber RD, Greenberger J, Larson M, Jaffe N, Li FP. Ovarian failure in long-term survivors of childhood malignancy. Am J Obstet Gynecol. 1981 Jan; 139(1):62-6.
    View in: PubMed
  357. Ezdinli EZ, Gelber R, Desai DV, Falkson G, Moertel CG, Hahn RG. Chemotherapy of advanced esophageal carcinoma: Eastern Cooperative Oncology Group experience. Cancer. 1980 Nov 15; 46(10):2149-53.
    View in: PubMed
  358. Earle JD, Gelber RD, Moertel CG, Hahn RG. A controlled evaluation of combined radiation and bleomycin therapy for squamous cell carcinoma of the esophagus. Int J Radiat Oncol Biol Phys. 1980 Jul; 6(7):821-6.
    View in: PubMed
  359. Snow JB, Gelber RD, Kramer S, Davis LW, Marcial VA, Lowry LD. Randomized preoperative and postoperative radiation therapy for patients with carcinoma of the head and neck: preliminary report. Laryngoscope. 1980 Jun; 90(6 Pt 1):930-45.
    View in: PubMed
  360. Sallan SE, Ritz J, Pesando J, Gelber R, O'Brien C, Hitchcock S, Coral F, Schlossman SF. Cell surface antigens: prognostic implications in childhood acute lymphoblastic leukemia. Blood. 1980 Mar; 55(3):395-402.
    View in: PubMed
  361. Carella RJ, Gelber R, Hendrickson F, Berry HC, Cooper JS. Value of radiation therapy in the management of patients with cerebral metastases from malignant melanoma: Radiation Therapy Oncology Group Brain Metastases Study I and II. Cancer. 1980 Feb 15; 45(4):679-83.
    View in: PubMed
  362. Borgelt B, Gelber R, Kramer S, Brady LW, Chang CH, Davis LW, Perez CA, Hendrickson FR. The palliation of brain metastases: final results of the first two studies by the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys. 1980 Jan; 6(1):1-9.
    View in: PubMed
  363. Dagher FJ, Gelber R, Reed W. Basilic vein to brachial artery, arteriovenous fistula for long-term hemodialysis: a five year follow-up. Proc Clin Dial Transplant Forum. 1980; 10:126-9.
    View in: PubMed
  364. Schoenfeld DA, Gelber RD. Designing and analyzing clinical trials which allow institutions to randomize patients to a subset of the treatments under study. Biometrics. 1979 Dec; 35(4):825-9.
    View in: PubMed
  365. Snow JB, Gelber RD, Kramer S, Davis LW, Marcial VA, Lowry LD. Evaluation of randomized preoperative and postoperative radiation therapy for supraglottic carcinoma. Preliminary report. Ann Otol Rhinol Laryngol. 1978 Sep-Oct; 87(5 Pt 1):686-91.
    View in: PubMed
  366. Borchardt KA, Baker M, Gelber R. Veillonella parvula septicemia and osteomyelitis. Ann Intern Med. 1977 Jan; 86(1):63-4.
    View in: PubMed
  367. Dagher F, Gelber R, Ramos E, Sadler J. The use of basilic vein and brachial artery as an A-V fistula for long term hemodialysis. J Surg Res. 1976 Apr; 20(4):373-6.
    View in: PubMed
  368. Borchardt KA, Gelber R, Botch V. Letter: Acid-fast smears in tuberculosis detection. Ann Intern Med. 1976 Mar; 84(3):344.
    View in: PubMed
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact Human Resources at faculty_serviceshms.harvard.edu. SPH faculty should contact Justin Sayde (jsaydehsph.harvard.edu).
Gelber's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts
_
Co-Authors
_
Similar People
_
Same Department
Physical Neighbors
_